Combination of antibody-drug conjugate and kinase inhibitor

JP2024161445APending Publication Date: 2024-11-19DAIICHI SANKYO CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
JP2024134653
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-26
Filing Date
2024-08-09
Publication Date
2024-11-19

AI Technical Summary

Benefits of technology

【0166】 本発明により、特定の抗体-薬物コンジュゲートとキナーゼ阻害剤が、組み合わされて投与されることを特徴とする医薬組成物、及び/又は、特定の抗体-薬物コンジュゲートとキナーゼ阻害剤が組み合わされて個体に投与されることを特徴とする治療方法を提供することができる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161445000001_ABST
    Figure 2024161445000001_ABST
Patent Text Reader

Abstract

To provide a pharmaceutical composition and a method for treatment by which a specific antibody-drug conjugate and a specific kinase inhibitor are administered in combination.SOLUTION: The present invention provides a method for treatment by which an antibody-drug conjugate, where a drug-linker represented by the following formula is conjugated to an antibody via a thioether bond, and a kinase inhibitor (e.g. a CDK4 / 6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, an AKT inhibitor, an ERK inhibitor, an MEK inhibitor, an RAF inhibitor, a CDK1 inhibitor, a CDK2 inhibitor, or a CHK1 inhibitor) are administered in combination to an individual.SELECTED DRAWING: Figure 11
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition characterized in that a specific antibody-drug conjugate and a kinase inhibitor are administered in combination, and / or a treatment method characterized in that a specific antibody-drug conjugate and a kinase inhibitor are administered in combination to an individual. [Background technology]

[0002] The proliferation of cancer cells and tumor angiogenesis are related to abnormal activation of intracellular signal transduction. Kinase inhibitors are drugs that exert antitumor effects by inhibiting kinases involved in abnormally activated intracellular signal transduction. Examples of such kinase inhibitors include CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, and NTRK inhibitors (Non-Patent Documents 1 to 11).

[0003] Antibody-drug conjugates (ADCs), which combine a cytotoxic drug with an antibody that binds to an antigen expressed on the surface of cancer cells and can be internalized into the cells, are expected to be able to selectively deliver drugs to cancer cells, thereby accumulating the drugs within the cancer cells and killing the cancer cells (Non-Patent Documents 12 to 16).

[0004] As one type of antibody-drug conjugate, an antibody-drug conjugate containing as components an antibody and a derivative of exatecan, which is a topoisomerase I inhibitor, is known (Patent Documents 1 to 8, Non-Patent Documents 17 to 21).

[0005] Patent Documents 1 to 8 describe that the above-mentioned antibody-drug conjugates can be administered together with various cancer therapeutic agents.

[0006] However, there are no known test results showing an excellent combined effect when the above antibody-drug conjugate is used in combination with the above kinase inhibitor, nor any literature describing scientific evidence suggesting such test results. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] International Publication No. 2014 / 057687 [Patent Document 2] International Publication No. 2014 / 061277 [Patent Document 3] International Publication No. 2015 / 098099 [Patent Document 4] International Publication No. 2015 / 115091 [Patent Document 5] International Publication No. 2015 / 146132 [Patent Document 6] International Publication No. 2015 / 155976 [Patent Document 7] International Publication No. 2015 / 155998 [Patent Document 8] International Publication No. 2018 / 212136 [Non-patent literature]

[0008] [Non-Patent Document 1] Otto T., et al., Nat. Rev. Cancer (2017) 17(2): 93-115. [Non-Patent Document 2] Zhang YJ., et al., Drug Discov. Today (2011) 16(7-8): 325-331. [Non-Patent Document 3] Zaytseva YY., et al., Cancer Lett. (2012) 319(1): 1-7.

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed Document 8

Non-licensed literature 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

[0009] The antibody-drug conjugate used in the present invention (antibody-drug conjugate containing an exatecan derivative as a component) has been confirmed to exhibit excellent antitumor effects even as a single agent. However, it is desirable to obtain a treatment method that can suppress the proliferation of cancer cells in a complex manner and exhibit a more excellent antitumor effect by using it in combination with other anticancer drugs with different mechanisms of action.

[0010] An objective of the present invention is to provide a pharmaceutical composition characterized in that a specific antibody-drug conjugate and a kinase inhibitor are administered in combination, and / or a treatment method characterized in that a specific antibody-drug conjugate and a kinase inhibitor are administered in combination to an individual. [Means for solving the problem]

[0011] Means for Solving the Problems The present inventors have conducted intensive studies to solve the above problems and have found that administering a specific antibody-drug conjugate in combination with a kinase inhibitor exhibits an excellent combined effect, thereby completing the present invention.

[0012] That is, the present invention provides the following [1] to

[1072] . [1] A pharmaceutical composition comprising an antibody-drug conjugate and a kinase inhibitor administered in combination, comprising: The antibody-drug conjugate has the formula

[0013] [ka]

[0014] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula: The pharmaceutical composition, wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors. [2] The pharmaceutical composition according to [1], wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors. [3] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a CDK4 / 6 inhibitor. [4] The pharmaceutical composition according to [3], wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof. [5] The pharmaceutical composition described in [2], wherein the kinase inhibitor is an mTOR inhibitor. [6] The pharmaceutical composition according to [5], wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof. [7] The pharmaceutical composition described in [2], wherein the kinase inhibitor is a PI3K inhibitor. [8] The pharmaceutical composition according to [7], wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof. [9] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a RAF inhibitor.

[10] The pharmaceutical composition according to [9], wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0015]

[11] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a VEGFR inhibitor.

[12] The pharmaceutical composition according to

[11] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[13] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a KIT inhibitor.

[14] The pharmaceutical composition according to

[13] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[15] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a RET inhibitor.

[16] The pharmaceutical composition described in

[15] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[17] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a PDGFR inhibitor.

[18] The pharmaceutical composition according to

[17] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[19] The pharmaceutical composition according to [2], wherein the kinase inhibitor is an FGFR inhibitor.

[20] The pharmaceutical composition according to

[19] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0016] [twenty one] The pharmaceutical composition according to [2], wherein the kinase inhibitor is an FLT3 inhibitor. [twenty two] The pharmaceutical composition according to

[21] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof. [twenty three] The pharmaceutical composition described in [2], wherein the kinase inhibitor is an ALK inhibitor. [twenty four] The pharmaceutical composition according to

[23] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof. [twenty five] The pharmaceutical composition according to [2], wherein the kinase inhibitor is a CSF-1R inhibitor.

[26] The pharmaceutical composition according to

[25] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[27] The pharmaceutical composition according to [2], wherein the kinase inhibitor is an EGFR inhibitor.

[28] The pharmaceutical composition according to

[27] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[29] The pharmaceutical composition described in [2], wherein the kinase inhibitor is a HER2 inhibitor.

[30] The pharmaceutical composition according to

[29] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0017]

[31] The pharmaceutical composition according to any one of [1] to

[30] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[32] The pharmaceutical composition according to

[31] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[33] The pharmaceutical composition described in

[32] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 of SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 of SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 of SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 of SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 of SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 of SEQ ID NO: 2.

[34] The pharmaceutical composition described in

[32] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[35] The pharmaceutical composition described in

[32] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[36] The pharmaceutical composition described in

[32] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[37] The pharmaceutical composition according to any one of

[32] to

[36] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[38] The pharmaceutical composition according to

[31] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[39] The pharmaceutical composition described in

[38] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[40] The pharmaceutical composition described in

[39] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0018]

[41] The pharmaceutical composition according to any one of

[38] to

[40] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[42] The pharmaceutical composition described in

[31] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[43] The pharmaceutical composition described in

[42] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[44] The pharmaceutical composition described in

[43] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[45] The pharmaceutical composition according to any one of

[42] to

[44] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[46] The pharmaceutical composition according to

[31] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[47] The pharmaceutical composition described in

[46] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[48] The pharmaceutical composition according to

[47] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[49] The pharmaceutical composition according to any one of

[46] to

[48] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[50] The pharmaceutical composition described in

[31] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0019]

[51] The pharmaceutical composition described in

[50] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[52] The pharmaceutical composition described in

[51] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[53] The pharmaceutical composition according to any one of

[50] to

[52] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[54] The pharmaceutical composition according to any one of [1] to

[53] , wherein the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[55] The pharmaceutical composition according to any one of [1] to

[54] , for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[56] The pharmaceutical composition described in

[55] for the treatment of breast cancer.

[57] The pharmaceutical composition described in

[55] for the treatment of colorectal cancer.

[58] The pharmaceutical composition described in

[55] for the treatment of gastric cancer.

[59] The pharmaceutical composition described in

[55] for the treatment of lung cancer.

[60] The pharmaceutical composition described in

[55] for the treatment of pancreatic cancer.

[61] The pharmaceutical composition described in

[55] for the treatment of kidney cancer.

[62] The pharmaceutical composition described in

[55] for the treatment of ovarian cancer.

[63] A pharmaceutical composition comprising an antibody-drug conjugate and a kinase inhibitor administered in combination, comprising: The antibody-drug conjugate has the formula

[0020] [ka]

[0021] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) an antibody-drug conjugate represented by the formula: The pharmaceutical composition, wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[64] The pharmaceutical composition described in

[63] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[65] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0022]

[66] The pharmaceutical composition according to

[65] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[67] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is an mTOR inhibitor.

[68] The pharmaceutical composition according to

[67] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[69] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is a PI3K inhibitor.

[70] The pharmaceutical composition according to

[69] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[71] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is a RAF inhibitor.

[72] The pharmaceutical composition according to

[71] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[73] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is a VEGFR inhibitor.

[74] The pharmaceutical composition according to

[73] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[75] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is a KIT inhibitor.

[0023]

[76] The pharmaceutical composition according to

[75] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[77] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is a RET inhibitor.

[78] The pharmaceutical composition described in

[77] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[79] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is a PDGFR inhibitor.

[80] The pharmaceutical composition according to

[79] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[81] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is an FGFR inhibitor.

[82] The pharmaceutical composition described in

[81] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[83] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is an FLT3 inhibitor.

[84] The pharmaceutical composition according to

[83] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[85] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is an ALK inhibitor.

[0024]

[86] The pharmaceutical composition according to

[85] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[87] The pharmaceutical composition according to

[64] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[88] The pharmaceutical composition according to

[87] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[89] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is an EGFR inhibitor.

[90] The pharmaceutical composition according to

[89] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0025]

[91] The pharmaceutical composition described in

[64] , wherein the kinase inhibitor is a HER2 inhibitor.

[92] The pharmaceutical composition according to

[91] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[93] The pharmaceutical composition according to any one of

[63] to

[92] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[94] The pharmaceutical composition according to

[93] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[95] The pharmaceutical composition described in

[94] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 of SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 of SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 of SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 of SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 of SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 of SEQ ID NO: 2.

[96] The pharmaceutical composition described in

[94] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[97] The pharmaceutical composition described in

[94] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[98] The pharmaceutical composition described in

[94] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 of SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 of SEQ ID NO: 2.

[99] The pharmaceutical composition according to any one of

[94] to

[98] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0100] The pharmaceutical composition according to

[93] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0026]

[0101] The pharmaceutical composition described in

[0100] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0102] A pharmaceutical composition described in

[0101] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0103] A pharmaceutical composition described in any one of

[0100] to

[0102] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0104] The pharmaceutical composition described in

[93] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0105] The pharmaceutical composition described in

[0104] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0106] The pharmaceutical composition described in

[0105] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0107] A pharmaceutical composition described in any one of

[0104] to

[0106] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0108] The pharmaceutical composition according to

[93] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0109] The pharmaceutical composition described in

[0108] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0110] A pharmaceutical composition described in

[0109] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0027]

[0111] A pharmaceutical composition described in any one of

[0108] to

[0110] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0112] The pharmaceutical composition described in

[93] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0113] The pharmaceutical composition described in

[0112] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0114] The pharmaceutical composition described in

[0113] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0115] A pharmaceutical composition described in any one of

[0112] to

[0114] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0116] The pharmaceutical composition according to any one of

[63] to

[0115] , wherein the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0028]

[0117] The pharmaceutical composition according to any one of

[63] to

[0116] , for the treatment of at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0118] A pharmaceutical composition described in

[0117] for the treatment of breast cancer.

[0119] A pharmaceutical composition described in

[0117] for the treatment of colon cancer.

[0120] A pharmaceutical composition described in

[0117] for the treatment of gastric cancer.

[0121] A pharmaceutical composition described in

[0117] for the treatment of lung cancer.

[0122] A pharmaceutical composition described in

[0117] for the treatment of pancreatic cancer.

[0123] A pharmaceutical composition described in

[0117] for the treatment of renal cancer.

[0124] A pharmaceutical composition described in

[0117] for the treatment of ovarian cancer.

[0125] A method of treatment comprising administering to an individual in need of treatment a combination of an antibody-drug conjugate and a kinase inhibitor, comprising: The antibody-drug conjugate has the formula

[0029] [ka]

[0030] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula: The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0126] The treatment method described in

[0125] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0127] A treatment method described in

[0126] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0128] The treatment method according to

[0127] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0129] A therapeutic method described in

[0126] , wherein the kinase inhibitor is an mTOR inhibitor.

[0130] The method of treatment according to

[0129] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0031]

[0131] A therapeutic method described in

[0126] , wherein the kinase inhibitor is a PI3K inhibitor.

[0132] The method for treatment according to

[0131] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, piralalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0133] A therapeutic method described in

[0126] , wherein the kinase inhibitor is a RAF inhibitor.

[0134] The treatment method according to

[0133] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0135] A therapeutic method described in

[0126] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0136] The treatment method according to

[0135] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0137] A treatment method described in

[0126] , wherein the kinase inhibitor is a KIT inhibitor.

[0138] The treatment method described in

[0137] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0139] A treatment method described in

[0126] , wherein the kinase inhibitor is a RET inhibitor.

[0140] A treatment method described in

[0139] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0032]

[0141] A therapeutic method described in

[0126] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0142] The treatment method described in

[0141] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0143] A therapeutic method described in

[0126] , wherein the kinase inhibitor is an FGFR inhibitor.

[0144] The treatment method described in

[0143] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0145] The treatment method described in

[0126] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0146] The method for treatment according to

[0145] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0147] A therapeutic method described in

[0126] , wherein the kinase inhibitor is an ALK inhibitor.

[0148] The treatment method described in

[0147] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0149] A therapeutic method described in

[0126] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0150] The treatment method according to

[0149] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0033]

[0151] A therapeutic method described in

[0126] , wherein the kinase inhibitor is an EGFR inhibitor.

[0152] The treatment method described in

[0151] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0153] A therapeutic method described in

[0126] , wherein the kinase inhibitor is a HER2 inhibitor.

[0154] The treatment method described in

[0153] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0155] A therapeutic method described in any one of

[0125] to

[0154] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0156] A therapeutic method described in

[0155] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0157] The treatment method described in

[0156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0158] The treatment method described in

[0156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain including a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain including a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0159] The treatment method described in

[0156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0160] The treatment method described in

[0156] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0034]

[0161] A therapeutic method described in any one of

[0156] to

[0160] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0162] A therapeutic method described in

[0155] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0163] The treatment method described in

[0162] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0164] A therapeutic method described in

[0163] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0165] A therapeutic method described in any one of

[0162] to

[0164] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0166] A therapeutic method described in

[0155] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0167] The treatment method described in

[0166] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0168] A therapeutic method described in

[0167] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0169] A therapeutic method described in any one of

[0166] to

[0168] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0170] A therapeutic method described in

[0155] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0035]

[0171] The treatment method described in

[0170] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0172] A therapeutic method described in

[0171] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0173] A therapeutic method described in any one of

[0170] to

[0172] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0174] A therapeutic method described in

[0155] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0175] The treatment method described in

[0174] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0176] A therapeutic method described in

[0175] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0177] A therapeutic method described in any one of

[0174] to

[0176] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0178] A therapeutic method described in any one of

[0125] to

[0177] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0179] A method for treating at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0180] A therapeutic method described in

[0179] for treating breast cancer.

[0036]

[0181] A therapeutic method described in

[0179] for treating colorectal cancer.

[0182] A therapeutic method described in

[0179] for treating gastric cancer.

[0183] A therapeutic method described in

[0179] for treating lung cancer.

[0184] A therapeutic method described in

[0179] for the treatment of pancreatic cancer.

[0185] A therapeutic method described in

[0179] for treating renal cancer.

[0186] A therapeutic method described in

[0179] for the treatment of ovarian cancer.

[0187] A method of treatment comprising administering to an individual in need of treatment a combination of an antibody-drug conjugate and a kinase inhibitor, comprising: The antibody-drug conjugate has the formula

[0037] [ka]

[0038] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) an antibody-drug conjugate represented by the formula: The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0188] The treatment method described in

[0187] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0189] A treatment method described in

[0188] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0190] The treatment method according to

[0189] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0039]

[0191] A therapeutic method described in

[0188] , wherein the kinase inhibitor is an mTOR inhibitor.

[0192] The method of treatment according to

[0191] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0193] A therapeutic method described in

[0188] , wherein the kinase inhibitor is a PI3K inhibitor.

[0194] The method for treatment according to

[0193] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0195] A treatment method described in

[0188] , wherein the kinase inhibitor is a RAF inhibitor.

[0196] The treatment method according to

[0195] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0197] A therapeutic method described in

[0188] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0198] The treatment method according to

[0197] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0199] A treatment method described in

[0188] , wherein the kinase inhibitor is a KIT inhibitor.

[0200] The treatment method described in

[0199] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0040]

[0201] A therapeutic method described in

[0188] , wherein the kinase inhibitor is a RET inhibitor.

[0202] The treatment method described in

[0201] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0203] A therapeutic method described in

[0188] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0204] The treatment method described in

[0203] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0205] A therapeutic method described in

[0188] , wherein the kinase inhibitor is an FGFR inhibitor.

[0206] The treatment method described in

[0205] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0207] The treatment method described in

[0188] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0208] The method for treatment according to

[0207] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0209] A therapeutic method described in

[0188] , wherein the kinase inhibitor is an ALK inhibitor.

[0210] The treatment method described in

[0209] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0041]

[0211] A therapeutic method described in

[0188] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0212] The treatment method described in

[0211] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0213] A therapeutic method described in

[0188] , wherein the kinase inhibitor is an EGFR inhibitor.

[0214] The treatment method described in

[0213] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0215] A therapeutic method described in

[0188] , wherein the kinase inhibitor is a HER2 inhibitor.

[0216] The treatment method described in

[0215] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0217] A therapeutic method described in any one of

[0187] to

[0216] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0218] A therapeutic method described in

[0217] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0219] The treatment method described in

[0218] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0220] The treatment method described in

[0218] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0042]

[0221] The treatment method described in

[0218] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0222] The treatment method described in

[0218] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0223] A therapeutic method described in any one of

[0218] to

[0222] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0224] A therapeutic method described in

[0217] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0225] The treatment method described in

[0224] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0226] A therapeutic method described in

[0225] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0227] A therapeutic method described in any one of

[0224] to

[0226] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0228] The therapeutic method described in

[0217] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0229] The treatment method described in

[0228] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0230] A therapeutic method described in

[0229] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0043]

[0231] A therapeutic method described in any one of

[0228] to

[0230] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0232] A therapeutic method described in

[0217] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0233] The treatment method described in

[0232] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0234] A therapeutic method described in

[0233] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0235] A therapeutic method described in any one of

[0232] to

[0234] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0236] A therapeutic method described in

[0217] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0237] The treatment method described in

[0236] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0238] A therapeutic method described in

[0237] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0239] A therapeutic method described in any one of

[0236] to

[0238] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0240] A therapeutic method described in any one of

[0187] to

[0231] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0044]

[0241] A method for treating at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0242] A therapeutic method described in

[0241] for treating breast cancer.

[0243] A therapeutic method described in

[0241] for treating colorectal cancer.

[0244] A therapeutic method described in

[0241] for treating gastric cancer.

[0245] A therapeutic method described in

[0241] for treating lung cancer.

[0246] A therapeutic method described in

[0241] for the treatment of pancreatic cancer.

[0247] A therapeutic method described in

[0241] for treating renal cancer.

[0248] A therapeutic method described in

[0241] for treating ovarian cancer.

[0249] A compound of the formula

[0045] [ka]

[0046] (wherein A represents the binding site to the antibody) and an antibody are bound to a drug linker represented by the following formula (I): The antibody-drug conjugate, wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0250] The antibody-drug conjugate according to

[0249] , wherein the kinase inhibitor is at least one selected from the group consisting of a CDK4 / 6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, a RAF inhibitor, a VEGFR inhibitor, a KIT inhibitor, a RET inhibitor, a PDGFR inhibitor, an FGFR inhibitor, an FLT3 inhibitor, an ALK inhibitor, a CSF-1R inhibitor, an EGFR inhibitor, and a HER2 inhibitor.

[0047]

[0251] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0252] The antibody-drug conjugate described in

[0251] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0253] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is an mTOR inhibitor.

[0254] The antibody-drug conjugate described in

[0253] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0255] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a PI3K inhibitor.

[0256] The antibody-drug conjugate according to

[0255] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0257] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a RAF inhibitor.

[0258] The antibody-drug conjugate described in

[0257] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0259] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0260] The antibody-drug conjugate according to

[0259] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0048]

[0261] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a KIT inhibitor.

[0262] The antibody-drug conjugate described in

[0261] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0263] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a RET inhibitor.

[0264] The antibody-drug conjugate described in

[0263] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0265] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0266] The antibody-drug conjugate according to

[0265] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0267] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is an FGFR inhibitor.

[0268] The antibody-drug conjugate described in

[0267] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0269] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0270] The antibody-drug conjugate described in

[0269] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, irolasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0049]

[0271] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is an ALK inhibitor.

[0272] The antibody-drug conjugate described in

[0271] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0273] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0274] The antibody-drug conjugate described in

[0273] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0275] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is an EGFR inhibitor.

[0276] The antibody-drug conjugate according to

[0275] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0277] The antibody-drug conjugate described in

[0250] , wherein the kinase inhibitor is a HER2 inhibitor.

[0278] The antibody-drug conjugate described in

[0277] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0279] An antibody-drug conjugate described in any one of

[0249] to

[0278] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0280] An antibody-drug conjugate described in

[0279] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0050]

[0281] The antibody-drug conjugate described in

[0280] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0282] The antibody-drug conjugate described in

[0280] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0283] The antibody-drug conjugate described in

[0280] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 2.

[0284] The antibody-drug conjugate described in

[0280] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0285] An antibody-drug conjugate described in any one of

[0280] to

[0284] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0286] An antibody-drug conjugate described in

[0279] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0287] The antibody-drug conjugate described in

[0286] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 4.

[0288] An antibody-drug conjugate described in

[0287] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0289] An antibody-drug conjugate described in any one of

[0286] to

[0288] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0290] The antibody-drug conjugate described in

[0279] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0051]

[0291] The antibody-drug conjugate described in

[0290] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0292] An antibody-drug conjugate described in

[0291] 1, in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0293] An antibody-drug conjugate described in any one of

[0290] to

[0292] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0294] An antibody-drug conjugate described in

[0279] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0295] The antibody-drug conjugate described in

[0294] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0296] An antibody-drug conjugate described in

[0295] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0297] An antibody-drug conjugate described in any one of

[0294] to

[0296] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0298] An antibody-drug conjugate described in

[0279] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0299] The antibody-drug conjugate described in

[0298] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0300] An antibody-drug conjugate described in

[0299] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0052]

[0301] An antibody-drug conjugate described in any one of

[0298] to

[0300] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0302] An antibody-drug conjugate described in any one of

[0249] to

[0301] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0303] The antibody-drug conjugate according to any one of

[0249] to

[0302] , for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0304] An antibody-drug conjugate described in

[0303] for the treatment of breast cancer.

[0305] An antibody-drug conjugate described in

[0303] for the treatment of colorectal cancer.

[0306] An antibody-drug conjugate described in

[0303] for the treatment of gastric cancer.

[0307] An antibody-drug conjugate described in

[0303] for the treatment of lung cancer.

[0308] An antibody-drug conjugate described in

[0303] for the treatment of pancreatic cancer.

[0309] An antibody-drug conjugate described in

[0303] for the treatment of renal cancer.

[0310] An antibody-drug conjugate described in

[0303] for the treatment of ovarian cancer.

[0311] A compound of the formula

[0053] [ka]

[0054] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) An antibody-drug conjugate represented by the formula: The antibody-drug conjugate, wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0312] The antibody-drug conjugate described in

[0311] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0313] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0314] The antibody-drug conjugate described in

[0313] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0315] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is an mTOR inhibitor.

[0055]

[0316] The antibody-drug conjugate described in

[0315] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0317] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a PI3K inhibitor.

[0318] The antibody-drug conjugate according to

[0317] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0319] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a RAF inhibitor.

[0320] The antibody-drug conjugate described in

[0319] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0056]

[0321] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0322] The antibody-drug conjugate according to

[0321] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0323] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a KIT inhibitor.

[0324] The antibody-drug conjugate according to

[0323] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0325] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a RET inhibitor.

[0326] The antibody-drug conjugate described in

[0325] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0327] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0328] The antibody-drug conjugate according to

[0327] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0329] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is an FGFR inhibitor.

[0330] The antibody-drug conjugate described in

[0329] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0057]

[0331] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0332] The antibody-drug conjugate described in

[0331] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, irolasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0333] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is an ALK inhibitor.

[0334] The antibody-drug conjugate described in

[0333] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0335] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0336] The antibody-drug conjugate described in

[0335] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0337] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is an EGFR inhibitor.

[0338] The antibody-drug conjugate according to

[0337] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0339] The antibody-drug conjugate described in

[0312] , wherein the kinase inhibitor is a HER2 inhibitor.

[0340] The antibody-drug conjugate described in

[0339] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0058]

[0341] An antibody-drug conjugate described in any one of

[0311] to

[0340] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0342] An antibody-drug conjugate described in

[0341] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0343] The antibody-drug conjugate described in

[0342] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0344] The antibody-drug conjugate described in

[0342] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0345] An antibody-drug conjugate described in

[0342] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 2.

[0059]

[0346] The antibody-drug conjugate described in

[0342] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0347] An antibody-drug conjugate described in any one of

[0342] to

[0346] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0348] An antibody-drug conjugate described in

[0341] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0349] The antibody-drug conjugate described in

[0348] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 4.

[0350] An antibody-drug conjugate described in

[0349] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0060]

[0351] An antibody-drug conjugate described in any one of

[0348] to

[0350] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0352] The antibody-drug conjugate described in

[0341] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0353] The antibody-drug conjugate described in

[0352] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0354] An antibody-drug conjugate described in

[0353] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0355] An antibody-drug conjugate described in any one of

[0352] to

[0354] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0356] An antibody-drug conjugate described in

[0341] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0357] The antibody-drug conjugate described in

[0356] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0358] An antibody-drug conjugate described in

[0357] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0359] An antibody-drug conjugate described in any one of

[0356] to

[0358] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0360] An antibody-drug conjugate described in

[0341] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0061]

[0361] The antibody-drug conjugate described in

[0360] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0362] An antibody-drug conjugate described in

[0361] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0363] An antibody-drug conjugate described in any one of

[0360] to

[0362] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0364] An antibody-drug conjugate described in any one of

[0311] to

[0363] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0365] The antibody-drug conjugate according to any one of

[0311] to

[0364] , for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0366] An antibody-drug conjugate described in

[0365] for the treatment of breast cancer.

[0367] An antibody-drug conjugate described in

[0365] for the treatment of colon cancer.

[0368] An antibody-drug conjugate described in

[0365] for the treatment of gastric cancer.

[0369] An antibody-drug conjugate described in

[0365] for the treatment of lung cancer.

[0370] An antibody-drug conjugate described in

[0365] for the treatment of pancreatic cancer.

[0371] An antibody-drug conjugate described in

[0365] for the treatment of renal cancer.

[0372] An antibody-drug conjugate described in

[0365] for the treatment of ovarian cancer.

[0373] For the manufacture of a medicament for treating a disease by administering in combination with a kinase inhibitor. formula

[0062] [ka]

[0063] (wherein A represents the binding site to the antibody) and an antibody linked via a thioether bond, The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0374] The use described in

[0373] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0375] The use described in

[0374] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0064]

[0376] The use described in

[0375] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0377] The use described in

[0374] , wherein the kinase inhibitor is an mTOR inhibitor.

[0378] The use described in

[0377] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0379] The use described in

[0374] , wherein the kinase inhibitor is a PI3K inhibitor.

[0380] The use according to

[0379] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, piralalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0381] The use described in

[0374] , wherein the kinase inhibitor is a RAF inhibitor.

[0382] The use described in

[0381] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0383] The use described in

[0374] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0384] The use described in

[0383] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0385] The use described in

[0374] , wherein the kinase inhibitor is a KIT inhibitor.

[0065]

[0386] The use described in

[0385] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0387] The use described in

[0374] , wherein the kinase inhibitor is a RET inhibitor.

[0388] The use described in

[0387] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0389] The use described in

[0374] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0390] The use described in

[0389] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0391] The use described in

[0374] , wherein the kinase inhibitor is an FGFR inhibitor.

[0392] The use described in

[0391] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0393] The use described in

[0374] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0394] The use described in

[0393] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, irolasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0395] The use described in

[0374] , wherein the kinase inhibitor is an ALK inhibitor.

[0066]

[0396] The use described in

[0395] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0397] The use described in

[0374] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0398] The use described in

[0397] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0399] The use described in

[0374] , wherein the kinase inhibitor is an EGFR inhibitor.

[0400] The use described in

[0399] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0067]

[0401] The use described in

[0374] , wherein the kinase inhibitor is a HER2 inhibitor.

[0402] The use described in

[0401] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0403] The use described in any one of

[0373] to

[0402] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0404] The use described in

[0403] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0405] The use described in

[0404] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0406] The use described in

[0404] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain including a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain including a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0407] The use described in

[0404] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0408] The use described in

[0404] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0409] The use described in any one of

[0404] to

[0408] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0410] The use described in

[0403] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0068]

[0411] The use described in

[0410] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0412] The use described in

[0411] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0413] The use described in any one of

[0410] to

[0412] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0414] The use described in

[0403] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0415] The use described in

[0414] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0416] The use described in

[0415] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0417] The use described in any one of

[0414] to

[0416] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0418] The use described in

[0403] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0419] The use described in

[0418] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0420] The use described in

[0419] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0069]

[0421] The use described in any one of

[0418] to

[0420] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0422] The use described in

[0403] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0423] The use described in

[0422] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0424] The use described in

[0423] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0425] The use described in any one of

[0422] to

[0424] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0426] The use described in any one of

[0373] to

[0425] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0427] The use described in any one of

[0373] to

[0426] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, renal cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0428] The use described in

[0427] for the treatment of breast cancer.

[0429] The use described in

[0427] for the treatment of colon cancer.

[0430] The use described in

[0427] for the treatment of gastric cancer.

[0070]

[0431] The use described in

[0427] for the treatment of lung cancer.

[0432] The use described in

[0427] for the treatment of pancreatic cancer.

[0433] The use described in

[0427] for the treatment of kidney cancer.

[0434] The use described in

[0427] for the treatment of ovarian cancer.

[0435] 2. A compound of formula (I) for the manufacture of a medicament for treating a disease by administering in combination with a kinase inhibitor,

[0071] [ka]

[0072] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) The use of an antibody-drug conjugate represented by The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0436] The use described in

[0435] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0437] The use described in

[0436] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0438] The use described in

[0437] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0439] The use described in

[0436] , wherein the kinase inhibitor is an mTOR inhibitor.

[0440] The use described in

[0439] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0073]

[0441] The use described in

[0436] , wherein the kinase inhibitor is a PI3K inhibitor.

[0442] The use according to

[0441] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0443] The use described in

[0436] , wherein the kinase inhibitor is a RAF inhibitor.

[0444] The use described in

[0443] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0445] The use described in

[0436] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0446] The use described in

[0445] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0447] The use described in

[0436] , wherein the kinase inhibitor is a KIT inhibitor.

[0448] The use described in

[0447] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0449] The use described in

[0436] , wherein the kinase inhibitor is a RET inhibitor.

[0450] The use described in

[0449] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0074]

[0451] The use described in

[0436] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0452] The use described in

[0451] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0453] The use described in

[0436] , wherein the kinase inhibitor is an FGFR inhibitor.

[0454] The use described in

[0453] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0455] The use described in

[0436] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0456] The use described in

[0455] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, irolasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0457] The use described in

[0436] , wherein the kinase inhibitor is an ALK inhibitor.

[0458] The use described in

[0457] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0459] The use described in

[0436] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0460] The use described in

[0459] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0075]

[0461] The use described in

[0436] , wherein the kinase inhibitor is an EGFR inhibitor.

[0462] The use described in

[0461] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0463] The use described in

[0436] , wherein the kinase inhibitor is a HER2 inhibitor.

[0464] The use described in

[0463] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0465] The use described in any one of

[0435] to

[0464] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0466] The use described in

[0465] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0467] The pharmaceutical composition described in

[0466] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 of SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 of SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 of SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 of SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 of SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 of SEQ ID NO: 2.

[0468] The pharmaceutical composition described in

[0466] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0469] The pharmaceutical composition described in

[0466] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 2.

[0470] The use described in

[0466] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0076]

[0471] The use described in any one of

[0466] to

[0470] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0472] The use described in

[0465] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0473] The use described in

[0472] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0474] The use described in

[0473] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0475] The use described in any one of

[0472] to

[0474] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0476] The use described in

[0465] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0477] The use described in

[0476] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0478] The use described in

[0477] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0479] The use described in any one of

[0476] to

[0478] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0480] The use described in

[0465] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0077]

[0481] The use described in

[0480] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0482] The use described in

[0481] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0483] The use described in any one of

[0480] to

[0482] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0484] The use described in

[0465] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0485] The use described in

[0484] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0486] The use described in

[0485] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0487] The use described in any one of

[0484] to

[0486] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0488] The use described in any one of

[0435] to

[0487] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0489] The use described in any one of

[0435] to

[0488] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, renal cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0490] The use described in

[0489] for the treatment of breast cancer.

[0078]

[0491] The use described in

[0489] for the treatment of colon cancer.

[0492] The use described in

[0489] for the treatment of gastric cancer.

[0493] The use described in

[0489] for the treatment of lung cancer.

[0494] The use described in

[0489] for the treatment of pancreatic cancer.

[0495] The use described in

[0489] for the treatment of kidney cancer.

[0496] The use described in

[0489] for the treatment of ovarian cancer.

[0497] A pharmaceutical composition comprising an antibody-drug conjugate and a kinase inhibitor administered in combination, comprising: The antibody-drug conjugate has the formula

[0079] [ka]

[0080] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,A pharmaceutical composition comprising at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0498] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0499] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0500] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0081]

[0501] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0502] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0503] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0504] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0505] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0506] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0507] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0508] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0509] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0510] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0082]

[0511] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0512] The pharmaceutical composition described in

[0497] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0513] The pharmaceutical composition described in any one of

[0497] to

[0512] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0514] The pharmaceutical composition described in

[0513] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0515] The pharmaceutical composition described in

[0514] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0516] The pharmaceutical composition described in

[0514] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0517] The pharmaceutical composition described in

[0514] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0518] The pharmaceutical composition described in

[0514] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0519] A pharmaceutical composition described in any one of

[0514] to

[0518] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0520] The pharmaceutical composition described in

[0513] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0083]

[0521] The pharmaceutical composition described in

[0520] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0522] The pharmaceutical composition described in

[0521] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0523] A pharmaceutical composition described in any one of

[0520] to

[0522] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0524] The pharmaceutical composition described in

[0513] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0525] The pharmaceutical composition described in

[0524] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0526] The pharmaceutical composition described in

[0525] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0527] A pharmaceutical composition described in any one of

[0524] to

[0526] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0528] The pharmaceutical composition described in

[0513] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0529] The pharmaceutical composition described in

[0528] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0530] A pharmaceutical composition described in

[0529] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-B7-H3 antibody is deleted.

[0084]

[0531] A pharmaceutical composition described in any one of

[0528] to

[0530] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0532] The pharmaceutical composition described in

[0513] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0533] The pharmaceutical composition described in

[0532] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0534] The pharmaceutical composition described in

[0533] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0535] A pharmaceutical composition described in any one of

[0532] to

[0534] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0536] A pharmaceutical composition described in any one of

[0497] to

[0535] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0537] The pharmaceutical composition described in any one of

[0497] to

[0536] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0538] A pharmaceutical composition described in

[0537] for the treatment of breast cancer.

[0539] A pharmaceutical composition described in

[0537] for the treatment of colorectal cancer.

[0540] A pharmaceutical composition described in

[0537] for the treatment of gastric cancer.

[0085]

[0541] A pharmaceutical composition described in

[0537] for the treatment of lung cancer.

[0542] A pharmaceutical composition described in

[0537] for the treatment of pancreatic cancer.

[0543] A pharmaceutical composition described in

[0537] for the treatment of kidney cancer.

[0544] A pharmaceutical composition described in

[0537] for the treatment of ovarian cancer.

[0545] A pharmaceutical composition comprising an antibody-drug conjugate and a kinase inhibitor administered in combination, comprising: The antibody-drug conjugate has the formula

[0086] [ka]

[0087] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) an antibody-drug conjugate represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,A pharmaceutical composition comprising at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0088]

[0546] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0547] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0548] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0549] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0550] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0551] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0552] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0553] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0554] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0555] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0089]

[0556] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0557] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0558] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0559] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0560] The pharmaceutical composition described in

[0545] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0561] The pharmaceutical composition described in any one of

[0545] to

[0560] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0562] The pharmaceutical composition described in

[0561] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0563] The pharmaceutical composition described in

[0562] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0564] The pharmaceutical composition described in

[0562] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0565] The pharmaceutical composition described in

[0562] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0090]

[0566] The pharmaceutical composition described in

[0562] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0567] A pharmaceutical composition described in any one of

[0562] to

[0566] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0568] The pharmaceutical composition described in

[0561] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0569] The pharmaceutical composition described in

[0568] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 4.

[0570] The pharmaceutical composition described in

[0569] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0571] A pharmaceutical composition described in any one of

[0568] to

[0570] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0572] The pharmaceutical composition described in

[0561] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0573] The pharmaceutical composition described in

[0572] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0574] The pharmaceutical composition described in

[0573] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0575] A pharmaceutical composition described in any one of

[0572] to

[0574] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0091]

[0576] The pharmaceutical composition described in

[0561] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0577] The pharmaceutical composition described in

[0576] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0578] A pharmaceutical composition described in

[0577] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-B7-H3 antibody is deleted.

[0579] A pharmaceutical composition described in any one of

[0576] to

[0578] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0580] The pharmaceutical composition described in

[0561] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0581] The pharmaceutical composition described in

[0580] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0582] The pharmaceutical composition described in

[0581] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0583] A pharmaceutical composition described in any one of

[0580] to

[0582] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0584] A pharmaceutical composition described in any one of

[0545] to

[0583] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0092]

[0585] The pharmaceutical composition described in any one of

[0545] to

[0584] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0586] A pharmaceutical composition described in

[0585] for the treatment of breast cancer.

[0587] A pharmaceutical composition described in

[0585] for the treatment of colon cancer.

[0588] A pharmaceutical composition described in

[0585] for the treatment of gastric cancer.

[0589] A pharmaceutical composition described in

[0585] for the treatment of lung cancer.

[0590] A pharmaceutical composition described in

[0585] for the treatment of pancreatic cancer.

[0591] A pharmaceutical composition described in

[0585] for the treatment of kidney cancer.

[0592] A pharmaceutical composition described in

[0585] for the treatment of ovarian cancer.

[0593] A method of treatment comprising administering to an individual in need of treatment a combination of an antibody-drug conjugate and a kinase inhibitor, comprising: The antibody-drug conjugate has the formula

[0093] [ka]

[0094] (wherein A represents the binding site to the antibody) and an antibody-drug conjugate in which the drug linker represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,A method for treating at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0095]

[0594] The treatment method described in

[0593] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0595] The treatment method described in

[0593] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0596] The treatment method described in

[0593] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0597] The treatment method described in

[0593] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0598] The treatment method described in

[0593] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0599] A therapeutic method described in

[0593] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0600] The treatment method described in

[0593] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0096]

[0601] A treatment method described in

[0593] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0602] A treatment method described in

[0593] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0603] The treatment method described in

[0593] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0604] The treatment method described in

[0593] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0605] A treatment method described in

[0593] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0606] A treatment method described in

[0593] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0607] The treatment method described in

[0593] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0608] The treatment method described in

[0593] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0609] A therapeutic method described in any one of

[0593] to

[0608] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0610] A therapeutic method described in

[0609] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0097]

[0611] The treatment method described in

[0610] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0612] The treatment method described in

[0610] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0613] The treatment method described in

[0610] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0614] The treatment method described in

[0610] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0615] A therapeutic method described in any one of

[0610] to

[0614] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0616] A therapeutic method described in

[0609] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0617] The treatment method described in

[0616] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0618] A therapeutic method described in

[0617] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0619] A therapeutic method described in any one of

[0616] to

[0618] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0620] A therapeutic method described in

[0609] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0098]

[0621] The treatment method described in

[0620] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0622] A therapeutic method described in

[0621] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0623] A therapeutic method described in any one of

[0620] to

[0622] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0624] A therapeutic method described in

[0609] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0625] The treatment method described in

[0624] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0626] A therapeutic method described in

[0625] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0627] A therapeutic method described in any one of

[0624] to

[0626] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0628] A therapeutic method described in

[0609] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0629] The treatment method described in

[0628] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0630] A therapeutic method described in

[0629] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0099]

[0631] A therapeutic method described in any one of

[0628] to

[0630] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0632] A therapeutic method described in any one of

[0593] to

[0631] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0633] A therapeutic method described in any one of

[0593] to

[0632] for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0634] A therapeutic method described in

[0633] for treating breast cancer.

[0635] A therapeutic method described in

[0633] for the treatment of colorectal cancer.

[0636] A therapeutic method described in

[0633] for treating gastric cancer.

[0637] A therapeutic method described in

[0633] for treating lung cancer.

[0638] A therapeutic method described in

[0633] for the treatment of pancreatic cancer.

[0639] A therapeutic method described in

[0633] for treating kidney cancer.

[0640] A therapeutic method described in

[0633] for treating ovarian cancer.

[0641] A method of treatment comprising administering to an individual in need of treatment a combination of an antibody-drug conjugate and a kinase inhibitor, comprising: The antibody-drug conjugate has the formula

[0100] [ka]

[0101] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) an antibody-drug conjugate represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,A method for treating at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0102]

[0642] A treatment method described in

[0641] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0643] A treatment method described in

[0641] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0644] A treatment method described in

[0641] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0645] A treatment method described in

[0641] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0646] The treatment method described in

[0641] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0647] A treatment method described in

[0641] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0648] A treatment method described in

[0641] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0649] A treatment method described in

[0641] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0650] A treatment method described in

[0641] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0103]

[0651] The treatment method described in

[0641] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0652] A treatment method described in

[0641] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0653] A treatment method described in

[0641] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0654] A treatment method described in

[0641] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0655] The treatment method described in

[0641] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0656] The treatment method described in

[0641] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0657] A therapeutic method described in any one of

[0641] to

[0656] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0658] A therapeutic method described in

[0657] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0659] The treatment method described in

[0658] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0104]

[0660] The treatment method described in

[0658] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0661] The treatment method described in

[0658] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0662] The treatment method described in

[0658] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0663] A therapeutic method described in any one of

[0658] to

[0662] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0664] A therapeutic method described in

[0657] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0665] The treatment method described in

[0664] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0666] A therapeutic method described in

[0665] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0667] A therapeutic method described in any one of

[0664] to

[0666] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0668] A therapeutic method described in

[0657] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0669] The treatment method described in

[0668] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0670] A therapeutic method described in

[0669] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0105]

[0671] A therapeutic method described in any one of

[0668] to

[0670] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0672] A therapeutic method described in

[0657] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0673] The treatment method described in

[0672] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0674] A therapeutic method described in

[0673] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0675] A therapeutic method described in any one of

[0672] to

[0674] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0676] A therapeutic method described in

[0657] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0677] The treatment method described in

[0676] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0678] A therapeutic method described in

[0677] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

[0679] A therapeutic method described in any one of

[0676] to

[0678] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0680] A therapeutic method described in any one of

[0641] to

[0679] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0106]

[0681] A therapeutic method described in any one of

[0641] to

[0680] for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0682] A therapeutic method described in

[0681] for treating breast cancer.

[0683] A therapeutic method described in

[0681] for the treatment of colon cancer.

[0684] A treatment method described in

[0681] for the treatment of gastric cancer.

[0685] A therapeutic method described in

[0681] for treating lung cancer.

[0686] A treatment method described in

[0681] for the treatment of pancreatic cancer.

[0687] A therapeutic method described in

[0681] for treating kidney cancer.

[0688] A therapeutic method described in

[0681] for treating ovarian cancer.

[0689] A compound of the formula

[0107] [ka]

[0108] (wherein A represents the binding site to the antibody) and an antibody are bound to a drug linker represented by the following formula (I): The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,An antibody-drug conjugate which is at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0109]

[0690] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0691] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0692] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0693] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0694] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0695] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0696] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0697] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0698] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0699] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0700] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0110]

[0701] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0702] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0703] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0704] The antibody-drug conjugate described in

[0689] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0705] An antibody-drug conjugate described in any one of

[0689] to

[0704] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0706] An antibody-drug conjugate described in

[0705] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0707] The antibody-drug conjugate described in

[0706] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0708] The antibody-drug conjugate described in

[0706] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0709] An antibody-drug conjugate described in

[0706] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 2.

[0111]

[0710] The antibody-drug conjugate described in

[0706] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0711] An antibody-drug conjugate described in any one of

[0706] to

[0710] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0712] An antibody-drug conjugate described in

[0705] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0713] The antibody-drug conjugate described in

[0712] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 4.

[0714] An antibody-drug conjugate described in

[0713] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0715] An antibody-drug conjugate described in any one of

[0712] to

[0714] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0716] An antibody-drug conjugate described in

[0705] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0717] The antibody-drug conjugate described in

[0716] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0718] An antibody-drug conjugate described in

[0717] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0719] An antibody-drug conjugate described in any one of

[0716] to

[0718] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0720] An antibody-drug conjugate described in

[0705] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0112]

[0721] The antibody-drug conjugate described in

[0720] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0722] An antibody-drug conjugate described in

[0721] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-B7-H3 antibody is deleted.

[0723] An antibody-drug conjugate described in any one of

[0720] to

[0722] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0724] An antibody-drug conjugate described in

[0705] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0725] The antibody-drug conjugate described in

[0724] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0726] An antibody-drug conjugate described in

[0725] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0727] An antibody-drug conjugate described in any one of

[0724] to

[0726] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0728] An antibody-drug conjugate described in any one of

[0689] to

[0727] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0729] The antibody-drug conjugate described in any one of

[0689] to

[0728] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0113]

[0730] An antibody-drug conjugate described in

[0729] for the treatment of breast cancer.

[0731] An antibody-drug conjugate described in

[0729] for the treatment of colon cancer.

[0732] An antibody-drug conjugate described in

[0729] for the treatment of gastric cancer.

[0733] An antibody-drug conjugate described in

[0729] for the treatment of lung cancer.

[0734] An antibody-drug conjugate described in

[0729] for the treatment of pancreatic cancer.

[0735] An antibody-drug conjugate described in

[0729] for the treatment of renal cancer.

[0736] An antibody-drug conjugate described in

[0729] for the treatment of ovarian cancer.

[0737] A compound of the formula

[0114] [ka]

[0115] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) An antibody-drug conjugate represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,An antibody-drug conjugate which is at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0116]

[0738] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0739] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0740] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0741] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0742] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0743] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0744] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0745] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0746] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0747] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0748] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0749] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0750] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0117]

[0751] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0752] The antibody-drug conjugate described in

[0737] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0753] An antibody-drug conjugate described in any one of

[0737] to

[0752] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0754] An antibody-drug conjugate described in

[0753] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0755] The antibody-drug conjugate described in

[0754] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0756] The antibody-drug conjugate described in

[0754] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain having a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain having a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0757] An antibody-drug conjugate described in

[0754] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 2.

[0758] The antibody-drug conjugate described in

[0754] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0759] An antibody-drug conjugate described in any one of

[0754] to

[0758] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0760] An antibody-drug conjugate described in

[0753] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0118]

[0761] An antibody-drug conjugate described in

[0760] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence described in SEQ ID NO: 4.

[0762] An antibody-drug conjugate described in

[0761] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0763] An antibody-drug conjugate described in any one of

[0760] to

[0762] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0764] An antibody-drug conjugate described in

[0753] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0765] The antibody-drug conjugate described in

[0764] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0766] An antibody-drug conjugate described in

[0765] , in which the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

[0767] An antibody-drug conjugate described in any one of

[0764] to

[0766] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0768] An antibody-drug conjugate described in

[0753] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0769] The antibody-drug conjugate described in

[0768] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0770] An antibody-drug conjugate described in

[0769] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-B7-H3 antibody is deleted.

[0119]

[0771] An antibody-drug conjugate described in any one of

[0768] to

[0770] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0772] An antibody-drug conjugate described in

[0753] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0773] The antibody-drug conjugate described in

[0772] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence described in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence described in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0774] An antibody-drug conjugate described in

[0773] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0775] An antibody-drug conjugate described in any one of

[0772] to

[0774] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0776] An antibody-drug conjugate described in any one of

[0737] to

[0775] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and administered simultaneously or at different times.

[0777] The antibody-drug conjugate described in any one of

[0737] to

[0776] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0778] An antibody-drug conjugate according to

[0777] for the treatment of breast cancer.

[0779] An antibody-drug conjugate described in

[0777] for the treatment of colon cancer.

[0780] An antibody-drug conjugate described in

[0777] for the treatment of gastric cancer.

[0120]

[0781] An antibody-drug conjugate described in

[0777] for the treatment of lung cancer.

[0782] An antibody-drug conjugate described in

[0777] for the treatment of pancreatic cancer.

[0783] An antibody-drug conjugate described in

[0777] for the treatment of renal cancer.

[0784] An antibody-drug conjugate described in

[0777] for the treatment of ovarian cancer.

[0785] 2. A compound of formula (I) for the manufacture of a medicament for treating a disease by administering in combination with a kinase inhibitor,

[0121] [ka]

[0122] (wherein A represents the binding site to the antibody) and an antibody linked via a thioether bond, The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,Use of at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0786] The use described in

[0785] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0787] The use described in

[0785] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0788] The use described in

[0785] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0789] The use described in

[0785] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0790] The use described in

[0785] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0123]

[0791] The use described in

[0785] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0792] The use described in

[0785] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0793] The use described in

[0785] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0794] The use described in

[0785] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0795] The use described in

[0785] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0796] The use described in

[0785] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0797] The use described in

[0785] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0798] The use described in

[0785] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0799] The use described in

[0785] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0800] The use described in

[0785] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0124]

[0801] The use described in any one of

[0785] to

[0800] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0802] The use described in

[0801] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0803] The use described in

[0802] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0804] The use described in

[0802] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain including a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain including a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0805] The use described in

[0802] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0806] The use described in

[0802] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0807] The use described in any one of

[0802] to

[0806] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0808] The use described in

[0801] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0809] The use described in

[0808] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0810] The use described in

[0809] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0125]

[0811] The use described in any one of

[0808] to

[0810] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0812] The use described in

[0801] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0813] The use described in

[0812] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0814] The use described in

[0813] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-TROP2 antibody is deleted.

[0815] The use described in any one of

[0812] to

[0814] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0816] The use described in

[0801] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0817] The use described in

[0816] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0818] The use described in

[0817] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

[0819] The use described in any one of

[0816] to

[0818] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0820] The use described in

[0801] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0126]

[0821] The use described in

[0820] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0822] The use described in

[0821] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0823] The use described in any one of

[0820] to

[0822] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0824] The use described in any one of

[0785] to

[0823] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0825] The use described in any one of

[0785] to

[0824] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, renal cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0826] The use described in

[0825] for the treatment of breast cancer.

[0827] The use described in

[0825] for the treatment of colorectal cancer.

[0828] The use described in

[0825] for the treatment of gastric cancer.

[0829] The use described in

[0825] for the treatment of lung cancer.

[0830] The use described in

[0825] for the treatment of pancreatic cancer.

[0831] The use described in

[0825] for the treatment of kidney cancer.

[0832] The use described in

[0825] for the treatment of ovarian cancer.

[0833] 2. A compound of formula (I) for the manufacture of a medicament for treating a disease by administering in combination with a kinase inhibitor,

[0127] [ka]

[0128] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) The use of an antibody-drug conjugate represented byThe kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,Use of at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[0129]

[0834] The use described in

[0833] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[0835] The use described in

[0833] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[0836] The use described in

[0833] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[0837] The use described in

[0833] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[0838] The use described in

[0833] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[0839] The use described in

[0833] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[0840] The use described in

[0833] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[0130]

[0841] The use described in

[0833] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[0842] The use described in

[0833] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[0843] The use described in

[0833] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[0844] The use described in

[0833] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0845] The use described in

[0833] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[0846] The use described in

[0833] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[0847] The use described in

[0833] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0848] The use described in

[0833] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0849] The use described in any one of

[0833] to

[0848] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

[0850] The use described in

[0849] , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

[0131]

[0851] The use described in

[0850] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2.

[0852] The use described in

[0850] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain including a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain including a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2.

[0853] The use described in

[0850] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2.

[0854] The use described in

[0850] , wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0855] The use described in any one of

[0850] to

[0854] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0856] The use described in

[0849] , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

[0857] The use described in

[0856] , wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4.

[0858] The use described in

[0857] , wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

[0859] The use described in any one of

[0856] to

[0858] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0860] The use described in

[0849] , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

[0132]

[0861] The use described in

[0860] , wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO: 6.

[0862] The use described in

[0861] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-TROP2 antibody is deleted.

[0863] The use described in any one of

[0860] to

[0862] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0864] The use described in

[0849] , wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

[0865] The use described in

[0864] , wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8.

[0866] The use described in

[0865] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-B7-H3 antibody is deleted.

[0867] The use described in any one of

[0864] to

[0866] , wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.5.

[0868] The use described in

[0849] , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

[0869] The use described in

[0868] , wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10.

[0870] The use described in

[0869] , in which the lysine residue at the carboxyl terminus of the heavy chain of an anti-CDH6 antibody is deleted.

[0133]

[0871] The use described in any one of

[0868] to

[0870] , wherein the average number of drug linker bonds per antibody in the antibody-drug conjugate is in the range of 7 to 8.

[0872] The use described in any one of

[0833] to

[0871] , characterized in that the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in separate formulations and are administered simultaneously or at different times.

[0873] The use described in any one of

[0833] to

[0872] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0874] The use described in

[0873] for the treatment of breast cancer.

[0875] The use described in

[0873] for the treatment of colon cancer.

[0876] The use described in

[0873] for the treatment of gastric cancer.

[0877] The use described in

[0873] for the treatment of lung cancer.

[0878] The use described in

[0873] for the treatment of pancreatic cancer.

[0879] The use described in

[0873] for the treatment of kidney cancer.

[0880] The use described in

[0873] for the treatment of ovarian cancer.

[0881] formula

[0134] [ka]

[0135] A pharmaceutical composition comprising an anticancer agent which releases a drug represented by the formula (I) in a tumor and a kinase inhibitor administered in combination, The pharmaceutical composition, wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0136]

[0882] The pharmaceutical composition described in

[0881] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0883] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0884] The pharmaceutical composition described in

[0883] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0885] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is an mTOR inhibitor.

[0886] The pharmaceutical composition described in

[0885] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0887] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a PI3K inhibitor.

[0888] The pharmaceutical composition according to

[0887] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0137]

[0889] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a RAF inhibitor.

[0890] The pharmaceutical composition described in

[0889] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0891] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0892] The pharmaceutical composition described in

[0891] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0893] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a KIT inhibitor.

[0894] The pharmaceutical composition described in

[0893] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0895] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a RET inhibitor.

[0896] The pharmaceutical composition described in

[0895] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0897] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0898] The pharmaceutical composition described in

[0897] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0899] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is an FGFR inhibitor.

[0900] The pharmaceutical composition described in

[0897] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0138]

[0901] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0902] The pharmaceutical composition described in

[0901] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0903] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is an ALK inhibitor.

[0904] The pharmaceutical composition described in

[0903] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0905] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0906] The pharmaceutical composition described in

[0905] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0907] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is an EGFR inhibitor.

[0908] The pharmaceutical composition described in

[0907] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0909] The pharmaceutical composition described in

[0882] , wherein the kinase inhibitor is a HER2 inhibitor.

[0910] The pharmaceutical composition described in

[0909] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0139]

[0911] The pharmaceutical composition described in any one of

[0881] to

[0910] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0912] formula

[0140] [ka]

[0141] A method for treating cancer, comprising administering to an individual in need of treatment a combination of an anticancer agent which releases a drug represented by the formula: The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0913] The treatment method described in

[0912] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0914] The treatment method described in

[0913] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0915] The treatment method described in

[0914] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0916] A therapeutic method described in

[0913] , wherein the kinase inhibitor is an mTOR inhibitor.

[0917] The treatment method described in

[0916] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0918] A therapeutic method described in

[0913] , wherein the kinase inhibitor is a PI3K inhibitor.

[0919] The method for treatment according to

[0918] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0920] The treatment method described in

[0913] , wherein the kinase inhibitor is a RAF inhibitor.

[0142]

[0921] The treatment method described in

[0920] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0922] The treatment method described in

[0913] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0923] The treatment method described in

[0922] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0924] A treatment method described in

[0913] , wherein the kinase inhibitor is a KIT inhibitor.

[0925] The treatment method described in

[0924] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0926] A treatment method described in

[0913] , wherein the kinase inhibitor is a RET inhibitor.

[0927] The treatment method described in

[0926] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0928] The treatment method described in

[0913] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0929] The treatment method described in

[0928] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0930] The treatment method described in

[0913] , wherein the kinase inhibitor is an FGFR inhibitor.

[0143]

[0931] The treatment method described in

[0930] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0932] The treatment method described in

[0913] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0933] The treatment method described in

[0932] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0934] A therapeutic method described in

[0913] , wherein the kinase inhibitor is an ALK inhibitor.

[0935] The treatment method described in

[0934] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0936] A therapeutic method described in

[0913] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0937] The treatment method described in

[0936] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0938] A therapeutic method described in

[0913] , wherein the kinase inhibitor is an EGFR inhibitor.

[0939] The treatment method described in

[0938] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0940] The treatment method described in

[0913] , wherein the kinase inhibitor is a HER2 inhibitor.

[0144]

[0941] The treatment method described in

[0940] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0942] A therapeutic method described in any one of

[0912] to

[0941] for treating at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0943] A compound of the formula

[0145] [ka]

[0146] An anticancer agent characterized by releasing a drug represented by the formula: The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0944] The anticancer agent described in

[0943] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0147]

[0945] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0946] The anticancer agent described in

[0945] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0947] An anticancer agent described in

[0944] , wherein the kinase inhibitor is an mTOR inhibitor.

[0948] The anticancer agent described in

[0947] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0949] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a PI3K inhibitor.

[0950] The anticancer agent according to

[0949] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, piralalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0951] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a RAF inhibitor.

[0952] The anticancer agent described in

[0951] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0953] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0954] The anticancer agent described in

[0953] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0955] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a KIT inhibitor.

[0956] The anticancer agent described in

[0955] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0957] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a RET inhibitor.

[0958] The anticancer agent described in

[0957] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0959] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0960] The anticancer agent described in

[0959] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0148]

[0961] The anticancer agent described in

[0944] , wherein the kinase inhibitor is an FGFR inhibitor.

[0962] The anticancer agent described in

[0961] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0963] The anticancer agent described in

[0944] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0964] The anticancer agent described in

[0963] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, irolasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0965] The anticancer agent described in

[0944] , wherein the kinase inhibitor is an ALK inhibitor.

[0966] The anticancer agent described in

[0965] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0967] An anticancer agent described in

[0944] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0968] The anticancer agent described in

[0967] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[0969] The anticancer agent described in

[0944] , wherein the kinase inhibitor is an EGFR inhibitor.

[0970] The anticancer agent described in

[0969] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0149]

[0971] The anticancer agent described in

[0944] , wherein the kinase inhibitor is a HER2 inhibitor.

[0972] The anticancer agent described in

[0971] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[0973] The anticancer agent described in any one of

[0943] to

[0972] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[0974] 2. A compound of formula (I) for the manufacture of a medicament for treating a disease by administering in combination with a kinase inhibitor,

[0150] [ka]

[0151] Use of an anticancer agent characterized by releasing a drug represented by the formula: The kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0975] The use described in

[0974] , wherein the kinase inhibitor is at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, RAF inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, FLT3 inhibitors, ALK inhibitors, CSF-1R inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0976] The use described in

[0975] , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

[0977] The use described in

[0976] , wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

[0978] The use described in

[0975] , wherein the kinase inhibitor is an mTOR inhibitor.

[0979] The use described in

[0978] , wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolisib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

[0980] The use described in

[0975] , wherein the kinase inhibitor is a PI3K inhibitor.

[0152]

[0981] The use according to

[0980] , wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilalalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

[0982] The use described in

[0975] , wherein the kinase inhibitor is a RAF inhibitor.

[0983] The use described in

[0982] , wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

[0984] The use described in

[0975] , wherein the kinase inhibitor is a VEGFR inhibitor.

[0153]

[0985] The use described in

[0984] , wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, irolasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

[0986] The use described in

[0975] , wherein the kinase inhibitor is a KIT inhibitor.

[0987] The use described in

[0986] , wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, irolasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0988] The use described in

[0975] , wherein the kinase inhibitor is a RET inhibitor.

[0989] The use described in

[0988] , wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

[0990] The use described in

[0975] , wherein the kinase inhibitor is a PDGFR inhibitor.

[0991] The use described in

[0990] , wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

[0992] The use described in

[0975] , wherein the kinase inhibitor is an FGFR inhibitor.

[0993] The use described in

[0992] , wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

[0994] The use described in

[0975] , wherein the kinase inhibitor is an FLT3 inhibitor.

[0995] The use described in

[0994] , wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, irolasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

[0996] The use described in

[0975] , wherein the kinase inhibitor is an ALK inhibitor.

[0997] The use described in

[0996] , wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

[0998] The use described in

[0975] , wherein the kinase inhibitor is a CSF-1R inhibitor.

[0999] The use described in

[0998] , wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

[1000] The use described in

[0975] , wherein the kinase inhibitor is an EGFR inhibitor.

[0154]

[1001] The use described in

[1000] , wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[1002] The use described in

[0975] , wherein the kinase inhibitor is a HER2 inhibitor.

[1003] The use described in

[1002] , wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

[1004] The use described in any one of

[0974] to

[1003] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, renal cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[1005] formula

[0155] [ka]

[0156] A pharmaceutical composition comprising an anticancer agent which releases a drug represented by the formula (I) in a tumor and a kinase inhibitor administered in combination, The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,A pharmaceutical composition comprising at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[1006] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[1007] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[1008] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[1009] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[1010] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[1011] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[1012] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[1013] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[1014] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[1015] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[1016] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[1017] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[1018] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[1019] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[1020] The pharmaceutical composition described in

[1005] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[0157]

[1021] The pharmaceutical composition according to any one of

[1005] to

[1020] , for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[1022] formula

[0158] [ka]

[0159] A method for treating cancer, comprising administering to an individual in need of treatment a combination of an anticancer agent which releases a drug represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,A method for treating the disease, comprising administering to the patient at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[1023] The treatment method described in

[1022] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[1024] The treatment method described in

[1022] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[1025] The treatment method described in

[1022] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[1026] The treatment method described in

[1022] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[1027] The treatment method described in

[1022] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[1028] The treatment method described in

[1022] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[1029] The treatment method described in

[1022] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[1030] The treatment method described in

[1022] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[1031] The treatment method described in

[1022] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[1032] The method of treatment according to

[1022] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[1033] The treatment method described in

[1022] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[1034] The treatment method described in

[1022] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[1035] The treatment method described in

[1022] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[1036] The treatment method described in

[1022] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[1037] The treatment method described in

[1022] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[1038] A method for treating at least one cancer selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

[1039] A compound of the formula

[0160] [ka]

[0161] An anticancer agent characterized by releasing a drug represented by the formula:The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,An anticancer agent which is at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[1040] The anticancer agent described in

[1039] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[1041] The anticancer agent described in

[1039] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[1042] The anticancer agent described in

[1039] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[1043] The anticancer agent described in

[1039] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[1044] The anticancer agent described in

[1039] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[1045] The anticancer agent described in

[1039] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[1046] The anticancer agent described in

[1039] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[1047] The anticancer agent described in

[1039] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[1048] The anticancer agent described in

[1039] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[1049] The anticancer agent described in

[1039] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[1050] The anticancer agent described in

[1039] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[0162]

[1051] The anticancer agent described in

[1039] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[1052] The anticancer agent described in

[1039] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[1053] The anticancer agent described in

[1039] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[1054] The anticancer agent described in

[1039] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[1055] The anticancer agent according to any one of

[1039] to

[1054] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, and melanoma.

[1056] 2. A compound of formula (I) for the manufacture of a medicament for treating a disease by administering in combination with a kinase inhibitor,

[0163] [ka]

[0164] Use of an anticancer agent characterized by releasing a drug represented by the formula: The kinase inhibitors include abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, KRX-0601, everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib buparlisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, rigosertib, ipatasertib, uprosertib, MK-2206, BAY1125976, AZD5363, TAS-117, ONC201, BVD-523, CC-90003, GDC-0994, LY3214996, MK-8353, trametinib, binimetinib, selumetinib, refametinib, pimasertib, cobimetinib, E6201, PD-0325901, RO5126766, G DC-0623, regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, dinaciclib, mircilib, seliciclib, alvocidib, roniciclib, voruciclib, AT7519, PHA-793887, CYC-065, MK-8776, LY2606368, LY2603618, CBP501, GDC-0425, CCT245737, AZD1775, volasertib, alisertib, ilorasertib, ENMD-2076, AMG900, imatinib, Dasatinib, bosutinib, nilotinib, ponatinib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ibrutinib, acalabrutinib, tirabrutinib, gilteritinib, quizartinib, midostaurin, brigatinib, crizotinib, ceritinib, alectinib, lorlatinib, ruxolitinib, tofacitinib, baricitinib, pacritinib, capmatinib, tepotinib, pexidartinib, BLZ-945, JNJ-40346527,Use of at least one selected from the group consisting of JNJ-28312141, entrectinib, GR-389988, gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, poziotinib, tucatinib, and mubritinib, and pharmacologically acceptable salts thereof.

[1057] The use described in

[1056] , wherein the kinase inhibitor is abemaciclib or a pharmacologically acceptable salt thereof.

[1058] The use described in

[1056] , wherein the kinase inhibitor is palbociclib or a pharmacologically acceptable salt thereof.

[1059] The use described in

[1056] , wherein the kinase inhibitor is everolimus or a pharmacologically acceptable salt thereof.

[1060] The use described in

[1056] , wherein the kinase inhibitor is taselisib or a pharmacologically acceptable salt thereof.

[1061] The use described in

[1056] , wherein the kinase inhibitor is alpelisib or a pharmacologically acceptable salt thereof.

[1062] The use described in

[1056] , wherein the kinase inhibitor is regorafenib or a pharmacologically acceptable salt thereof.

[1063] The use described in

[1056] , wherein the kinase inhibitor is cabozantinib or a pharmacologically acceptable salt thereof.

[1064] The use described in

[1056] , wherein the kinase inhibitor is sunitinib or a pharmacologically acceptable salt thereof.

[1065] The use described in

[1056] , wherein the kinase inhibitor is nintedanib or a pharmacologically acceptable salt thereof.

[1066] The use described in

[1056] , wherein the kinase inhibitor is brigatinib or a pharmacologically acceptable salt thereof.

[1067] The use described in

[1056] , wherein the kinase inhibitor is erlotinib or a pharmacologically acceptable salt thereof.

[1068] The use described in

[1056] , wherein the kinase inhibitor is neratinib or a pharmacologically acceptable salt thereof.

[1069] The use described in

[1056] , wherein the kinase inhibitor is poziotinib or a pharmacologically acceptable salt thereof.

[1070] The use described in

[1056] , wherein the kinase inhibitor is tucatinib or a pharmacologically acceptable salt thereof.

[0165]

[1071] The use described in

[1056] , wherein the kinase inhibitor is mubritinib or a pharmacologically acceptable salt thereof.

[1072] The use described in any one of

[1056] to

[1071] for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial carcinoma, prostate cancer, bladder cancer, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma. Effect of the Invention

[0166] The present invention can provide a pharmaceutical composition characterized in that a specific antibody-drug conjugate and a kinase inhibitor are administered in combination, and / or a treatment method characterized in that a specific antibody-drug conjugate and a kinase inhibitor are administered in combination to an individual. [Brief description of the drawings]

[0167] [Figure 1]FIG. 1 shows the amino acid sequence of the anti-HER2 antibody heavy chain (SEQ ID NO:1). [Diagram 2] FIG. 2 shows the amino acid sequence of the anti-HER2 antibody light chain (SEQ ID NO:2). [Diagram 3] FIG. 2 shows the amino acid sequence of the anti-HER3 antibody heavy chain (SEQ ID NO: 3). [Figure 4] FIG. 1 shows the amino acid sequence of the anti-HER3 antibody light chain (SEQ ID NO: 4). [Diagram 5] FIG. 1 shows the amino acid sequence of the anti-TROP2 antibody heavy chain (SEQ ID NO:5). [Figure 6] FIG. 1 shows the amino acid sequence of the anti-TROP2 antibody light chain (SEQ ID NO: 6). [Figure 7] FIG. 7 shows the amino acid sequence of the anti-B7-H3 antibody heavy chain (SEQ ID NO:7). [Figure 8] FIG. 1 shows the amino acid sequence of the anti-B7-H3 antibody light chain (SEQ ID NO: 8). [Figure 9] FIG. 1 shows the amino acid sequence of the anti-CDH6 antibody heavy chain (SEQ ID NO: 9). [Figure 10] FIG. 1 shows the amino acid sequence of the anti-CDH6 antibody light chain (SEQ ID NO: 10). [Figure 11] FIG. 1 shows the tumor growth inhibitory effects of a group administered antibody-drug conjugate (1) or everolimus alone, and a group administered antibody-drug conjugate (1) in combination with everolimus, in mice subcutaneously implanted with MDA-MB-453 cells. [Figure 12] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (1) and taselisib single-agent administration group, and the antibody-drug conjugate (1) and taselisib combined administration group in mice subcutaneously implanted with MDA-MB-453 cells. [Figure 13] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (1) and abemaciclib monotherapy groups, as well as the antibody-drug conjugate (1) and abemaciclib combination therapy group in mice subcutaneously implanted with MDA-MB-453 cells. [Figure 14]FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (1) and everolimus monotherapy groups, and the antibody-drug conjugate (1) and everolimus combination therapy group in mice subcutaneously implanted with JIMT-1 cells. [Figure 15] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (1) and regorafenib single-agent administration group, and the antibody-drug conjugate (1) and regorafenib combined administration group in mice subcutaneously implanted with COLO201 cells. [Figure 16] FIG. 1 shows the tumor growth inhibitory effects in mice subcutaneously implanted with KPL-4 cells, in groups administered antibody-drug conjugate (1) or tucatinib alone, and in a group administered antibody-drug conjugate (1) in combination with tucatinib. [Figure 17] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (1) and tucatinib single-agent administration groups, as well as the antibody-drug conjugate (1) and tucatinib combined administration group, in mice subcutaneously implanted with MDA-MB-453 cells. [Figure 18] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (1) and tucatinib single-agent administration groups, and the antibody-drug conjugate (1) and tucatinib combined administration group in mice subcutaneously implanted with NCI-N87 cells. [Figure 19] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (2) and neratinib single-agent administration groups, as well as the antibody-drug conjugate (2) and neratinib combined administration group in mice subcutaneously implanted with KPL-4 cells. [Figure 20] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (3) and cabozantinib single-agent administration groups, and the antibody-drug conjugate (3) and cabozantinib combined administration group in mice subcutaneously implanted with 786-O cells. [Figure 21]FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (2) and palbociclib single-agent administration groups, and the antibody-drug conjugate (2) and palbociclib combined administration group in mice subcutaneously implanted with MDA-MB-453 cells. [Figure 22] FIG. 1 shows the tumor growth inhibitory effects of the antibody-drug conjugate (2) and alpelisib single-agent administration groups, and the antibody-drug conjugate (2) and alpelisib combined administration group in mice subcutaneously implanted with MDA-MB-453 cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0168] A preferred embodiment for carrying out the present invention will be described below. Note that the embodiment described below is an example of a typical embodiment of the present invention, and the scope of the present invention is not to be interpreted narrowly by this embodiment.

[0169] 1. Antibody-drug conjugates The antibody-drug conjugate used in the present invention has the formula

[0170] [ka]

[0171] (wherein A represents the binding site to the antibody) and an antibody via a thioether bond.

[0172] In the present invention, a partial structure of an antibody-drug conjugate consisting of a linker and a drug is referred to as a "drug linker". This drug linker is bonded to a thiol group (in other words, a sulfur atom of a cysteine ​​residue) generated at disulfide bond sites between antibody chains (two sites between heavy chains and two sites between heavy chains and light chains).

[0173] The drug linker of the present invention is based on the topoisomerase I inhibitor exatecan (IUPAC name: (1S,9S)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, (chemical name: (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione)). Exatecan has the formula

[0174] [ka]

[0175] It is a camptothecin derivative having an antitumor effect, represented by the following formula:

[0176] The antibody-drug conjugate used in the present invention may also be represented by the following formula:

[0177] [ka]

[0178] Here, the drug linker is bound to the antibody via a thioether bond, and n is synonymous with the so-called average drug binding number (DAR; Drug-to-Antibody Ratio), and indicates the average number of drug linkers bound per antibody. The antibody-drug conjugate used in the present invention is transported into cancer cells, and then the linker moiety is cleaved, formula

[0179] [ka]

[0180] This liberates a compound represented by the formula:

[0181] The above compound is considered to be the main component of the antitumor activity of the antibody-drug conjugate used in the present invention, and has been confirmed to have a topoisomerase I inhibitory effect (Ogitani Y. et al., Clinical Cancer Research, 2016, Oct 15;22(20):5097-5108, Epub 2016 Mar 29).

[0182] In addition, the antibody-drug conjugate used in the present invention is also known to have a bystander effect (Ogitani Y. et al., Cancer Science (2016) 107, 1039-1046).

[0183] This bystander effect is exerted when the antibody-drug conjugate used in the present invention is internalized into target-expressing cancer cells, and the compound is released and exerts an antitumor effect on nearby cancer cells that do not express the target.

[0184] This bystander effect is also exhibited as an excellent antitumor effect when the antibody-drug conjugate of the present invention is used in combination with a kinase inhibitor.

[0185] 2. Antibodies in antibody-drug conjugates The antibody in the antibody-drug conjugate used in the present invention may be derived from any species, but is preferably derived from human, rat, mouse, and rabbit. If the antibody is derived from a species other than human, it is preferably chimerized or humanized using well-known techniques. The antibody of the present invention may be a polyclonal antibody or a monoclonal antibody, but is preferably a monoclonal antibody.

[0186] The antibody in the antibody-drug conjugate used in the present invention preferably has the property of targeting cancer cells, and preferably has the property of recognizing cancer cells, the property of binding to cancer cells, the property of being taken up and internalized into cancer cells, and / or cytocidal activity against cancer cells.

[0187] The binding of the antibody to the cancer cells can be confirmed by flow cytometry. The uptake of the antibody into the cancer cells can be confirmed by (1) an assay in which the antibody taken up into the cells is visualized by a fluorescence microscope using a secondary antibody (fluorescently labeled) that binds to the therapeutic antibody (Cell Death and Differentiation (2008) 15, 751-761), (2) an assay in which the amount of fluorescence taken up into the cells is measured using a secondary antibody (fluorescently labeled) that binds to the therapeutic antibody (Molecular Biology of the Cell Vol. 15, 5268-5282, December 2004), or (3) a Mab-ZAP assay in which an immunotoxin that binds to the therapeutic antibody is released when the antibody is taken up into the cells, thereby suppressing cell proliferation (Bio Techniques 28:162-165, January 2000). A recombinant complex protein of the catalytic domain of diphtheria toxin and protein G can also be used as the immunotoxin.

[0188] The antitumor activity of an antibody can be confirmed in vitro by measuring the inhibitory activity against cell proliferation. For example, a cancer cell line that overexpresses the antibody's target protein is cultured, and the antibody is added to the culture system at various concentrations to measure the inhibitory activity against focus formation, colony formation, and spheroid proliferation. In vivo, the antitumor activity can be confirmed, for example, by administering the antibody to nude mice transplanted with a cancer cell line that highly expresses the target protein, and measuring the changes in the cancer cells.

[0189] It is preferable that the antibody itself has an antitumor effect, but since the antibody-drug conjugate is bound to a compound that exerts an antitumor effect, the antibody itself does not necessarily have an antitumor effect. For the purpose of exerting the cytotoxicity of the antitumor compound specifically and selectively in cancer cells, it is important and preferable that the antibody has the property of being internalized and transferred into the cancer cells.

[0190] The antibody in the antibody-drug conjugate used in the present invention can be obtained by known means. For example, it can be obtained by immunizing an animal with an antigenic polypeptide, and collecting and purifying the antibody produced in the body using a method commonly used in this field. The origin of the antigen is not limited to humans, and an animal can also be immunized with an antigen derived from an animal other than humans, such as a mouse or a rat. In this case, an antibody applicable to a human disease can be selected by testing the cross-reactivity of the obtained antibody that binds to a heterologous antigen with a human antigen.

[0191] Alternatively, a hybridoma can be established by fusing an antibody-producing cell that produces an antibody against an antigen with a myeloma cell according to known methods (e.g., Kohler and Milstein, Nature (1975) 256, p. 495-497; Kennet, R. ed., Monoclonal Antibodies, p. 365-367, Plenum Press, NY (1980)), thereby obtaining a monoclonal antibody.

[0192] The antigen can be obtained by genetically engineering a gene encoding an antigen protein in a host cell to produce it. Specifically, a vector capable of expressing an antigen gene is prepared, introduced into a host cell to express the gene, and the expressed antigen is purified. Antibodies can also be obtained by immunizing an animal with the above genetically engineered antigen-expressing cells or a cell line expressing the antigen.

[0193] The antibody in the antibody-drug conjugate used in the present invention is preferably a genetically engineered antibody that has been artificially modified for the purpose of reducing heterologous antigenicity against humans, such as a chimeric antibody or a humanized antibody, or is preferably an antibody having only the genetic sequence of an antibody derived from humans, i.e., a human antibody. These antibodies can be produced using known methods.

[0194] Chimeric antibodies include antibodies whose variable and constant regions are of different species, such as chimeric antibodies in which the variable region of an antibody derived from a mouse or rat is joined to a constant region derived from a human (Proc. Natl. Acad. Sci. USA, 81, 6851-6855, (1984)).

[0195] Examples of humanized antibodies include antibodies in which only the complementarity determining region (CDR) of a heterologous antibody has been incorporated into an antibody of human origin (Nature (1986) 321, p. 522-525), antibodies in which not only the CDR sequence of a heterologous antibody but also some framework amino acid residues of the heterologous antibody have been grafted onto a human antibody by CDR grafting (WO 90 / 07861), and antibodies humanized using a gene conversion mutagenesis strategy (U.S. Pat. No. 5,821,337).

[0196] Examples of human antibodies include antibodies produced using human antibody-producing mice having a human chromosome fragment containing the heavy and light chain genes of a human antibody (see, for example, Tomizuka, K. et al., Nature Genetics (1997) 16, p.133-143; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, p.3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol.10, p.69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., Proc. Natl. Acad. Sci. USA (2000) 97, p.722-727). Alternatively, antibodies obtained by phage display selected from a human antibody library can also be used (see, for example, Wormstone, IM et. al, Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Carmen, S. et. al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p. 189-203; Siriwardena, D. et. al., Ophthalmology (2002) 109 (3), p. 427-431).

[0197] The antibody in the antibody-drug conjugate used in the present invention also includes modified antibodies. The modified antibody means an antibody according to the present invention that has been chemically or biologically modified. Chemical modifications include those having a chemical moiety bonded to the amino acid backbone, or a chemical moiety bonded to an N- or O-linked carbohydrate chain. Biological modifications include those that have been post-translationally modified (e.g., addition of an N- or O-linked sugar chain, processing of the N- or C-terminus, deamidation, isomerization of aspartic acid, oxidation of methionine, etc.), and those that have been expressed using a prokaryotic host cell to add a methionine residue to the N-terminus. In addition, those labeled to enable detection or isolation of the antibody or antigen according to the present invention, such as enzyme-labeled, fluorescent-labeled, and affinity-labeled, are also included in the meaning of such modified antibodies. Such modified antibodies according to the present invention are useful for improving the stability and blood retention of the antibody, reducing antigenicity, and detecting or isolating the antibody or antigen, etc.

[0198] In addition, antibody-dependent cellular cytotoxicity can be enhanced by regulating the sugar chain modification bound to the antibody of the present invention (glycosylation, defucosylation, etc.). Techniques for regulating the sugar chain modification of antibodies are known, including, but not limited to, International Publication Nos. WO 99 / 54342, WO 00 / 61739, WO 02 / 31140, WO 2007 / 133855, and WO 2013 / 120066. The antibody of the present invention also includes an antibody in which the sugar chain modification is regulated.

[0199] It is known that antibodies produced in cultured mammalian cells have a deletion of the lysine residue at the carboxyl terminus of their heavy chains (Journal of Chromatography A, 705: 129-134 (1995)), and also have a deletion of two amino acid residues, glycine and lysine, at the carboxyl terminus of the heavy chain, and amidation of the proline residue located at the carboxyl terminus (Analytical Biochemistry, 360: 75-83 (2007)). However, these deletions and modifications of the heavy chain sequence do not affect the antigen-binding ability and effector functions (complement activation, antibody-dependent cellular cytotoxicity, etc.) of the antibody. Therefore, the antibody according to the present invention also includes antibodies and functional fragments of the antibodies that have been modified in this way, and also includes deletion products in which one or two amino acids have been deleted at the carboxyl terminus of the heavy chain, and deletion products that have been amidated (for example, heavy chains in which the proline residue at the carboxyl terminus has been amidated). However, as long as the antigen-binding ability and effector function are maintained, the deletion of the carboxyl terminus of the heavy chain of the antibody according to the present invention is not limited to the above types. The two heavy chains constituting the antibody according to the present invention may be any one type of heavy chain selected from the group consisting of full-length and the above deletions, or may be a combination of any two types. The quantitative ratio of each deletion may be influenced by the type and culture conditions of the cultured mammalian cells producing the antibody according to the present invention, but the antibody according to the present invention is preferably one in which one amino acid residue is deleted at the carboxyl terminus of both of the two heavy chains.

[0200] The isotype of the antibody according to the present invention can be, for example, IgG (IgG1, IgG2, IgG3, IgG4), etc., and preferably IgG1 or IgG2.

[0201] The antibody in the antibody-drug conjugate used in the present invention is not particularly limited, and examples thereof include anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, anti-B7-H3 antibody, anti-CDH6 antibody, anti-CD3 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD37 antibody, anti-CD56 antibody, anti-CD98 antibody, anti-DR5 antibody, anti-EGFR antibody, anti-EPHA2 antibody, anti-FGFR2 antibody, anti-FGFR4 antibody, anti-FOLR1 antibody, anti-VEGF antibody, anti-CD20 antibody, anti-C Examples of antibodies include D22 antibody, anti-CD70 antibody, anti-PSMA antibody, anti-CEA antibody, anti-Mesothelin antibody, anti-A33 antibody, anti-CanAg antibody, anti-Cripto antibody, anti-G250 antibody, anti-MUC1 antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-Tenascin-C antibody, and anti-SLC44A4 antibody, and preferred examples of such antibodies include anti-HER2 antibody, anti-HER3 antibody, anti-TROP2 antibody, anti-B7-H3 antibody, and anti-CDH6 antibody.

[0202] In the present invention, the term "anti-HER2 antibody" refers to an antibody that specifically binds to HER2 (Human Epidermal Growth Factor Receptor Type 2; ErbB-2), and preferably has the activity of being internalized into HER2-expressing cells upon binding to HER2.

[0203] Examples of anti-HER2 antibodies include trastuzumab (US Pat. No. 5,821,337) and pertuzumab (International Publication No. WO 01 / 00245), and preferably trastuzumab.

[0204] In the present invention, the term "anti-HER3 antibody" refers to an antibody that specifically binds to HER3 (Human Epidermal Growth Factor Receptor Type 3; ErbB-3), and preferably has the activity of being internalized into HER3-expressing cells upon binding to HER3.

[0205] Examples of anti-HER3 antibodies include Patritumab (U3-1287), U1-59 (WO 2007 / 077028), MM-121 (Seribantumab), the anti-ERBB3 antibodies described in WO 2008 / 100624, RG-7116 (Lumretuzumab), and LJM-716 (Elgemtumab), and preferred examples include Patritumab and U1-59.

[0206] In the present invention, the term "anti-TROP2 antibody" refers to an antibody that specifically binds to TROP2 (TACSTD2: Tumor-associated calcium signal transducer 2; EGP-1), and preferably has the activity of being internalized into TROP2-expressing cells by binding to TROP2.

[0207] An example of an anti-TROP2 antibody is hTINA1-H1L1 (WO 2015 / 098099).

[0208] In the present invention, the term "anti-B7-H3 antibody" refers to an antibody that specifically binds to B7-H3 (B cell antigen #7 homolog 3; PD-L3; CD276), and preferably has the activity of being internalized into B7-H3-expressing cells through binding to B7-H3.

[0209] An example of an anti-B7-H3 antibody is M30-H1-L4 (WO 2014 / 057687).

[0210] In the present invention, the term "anti-CDH6 antibody" refers to an antibody that specifically binds to CDH6 (Cadherin-6), and preferably has the activity of being internalized into CDH6-expressing cells through binding to CDH6.

[0211] An example of an anti-CDH6 antibody is H01L02 (International Publication No. 2018 / 212136).

[0212] 3. Preparation of Antibody-drug Conjugates The drug linker intermediate used in the preparation of the antibody-drug conjugate of the present invention is represented by the following formula:

[0213] [ka]

[0214] The drug linker intermediate shown above is N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4': It can be expressed by the chemical name, "6,7]indolizino[1,2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamide," and can be produced with reference to the descriptions in WO 2014 / 057687, WO 2015 / 098099, WO 2015 / 115091, WO 2015 / 155998, and WO 2019 / 044947.

[0215] The antibody-drug conjugate used in the present invention can be prepared by reacting the above-mentioned drug linker intermediate with an antibody having a thiol group (also called a sulfhydryl group).

[0216] An antibody having a sulfhydryl group can be obtained by a method well known to those skilled in the art (Hermanson, G. T, Bioconjugate Techniques, pp.56-136, pp.456-493, Academic Press (1996)). For example, a reducing agent such as tris(2-carboxyethyl)phosphine hydrochloride (TCEP) can be used in an amount of 0.3 to 3 molar equivalents per antibody interchain disulfide, and reacted with the antibody in a buffer containing a chelating agent such as ethylenediaminetetraacetic acid (EDTA), to obtain an antibody having a sulfhydryl group in which the antibody interchain disulfide has been partially or completely reduced.

[0217] Additionally, 2-20 molar equivalents of drug linker intermediate can be used per antibody bearing a sulfhydryl group to produce antibody-drug conjugates with 2-8 drugs attached per antibody.

[0218] The average number of drugs bound per antibody molecule in the produced antibody-drug conjugate can be calculated, for example, by a method in which the UV absorbance of the antibody-drug conjugate and its conjugation precursor are measured at two wavelengths, 280 nm and 370 nm (UV method), or by a method in which the antibody-drug conjugate is treated with a reducing agent, and each of the resulting fragments is quantified by HPLC measurement and then calculated (HPLC method).

[0219] Conjugation of an antibody and a drug linker intermediate, and calculation of the average number of drugs bound per antibody molecule of an antibody-drug conjugate can be carried out with reference to the descriptions in WO 2014 / 057687, WO 2015 / 098099, WO 2015 / 115091, WO 2015 / 155998, WO 2017 / 002776, WO 2018 / 212136, etc.

[0220] In the present invention, the term "anti-HER2 antibody-drug conjugate" refers to an antibody-drug conjugate according to the present invention in which the antibody is an anti-HER2 antibody.

[0221] The anti-HER2 antibody is preferably an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 33 in SEQ ID NO: 1, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 51 to 58 in SEQ ID NO: 1, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 97 to 109 in SEQ ID NO: 1, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 27 to 32 in SEQ ID NO: 2, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 52 in SEQ ID NO: 2, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 89 to 97 in SEQ ID NO: 2, More preferably, the antibody comprises a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO: 2, Even more preferably, it is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 2, or an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 in SEQ ID NO: 2.

[0222] The average number of drug linker bonds per antibody in the anti-HER2 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.

[0223] Anti-HER2 antibody-drug conjugates can be produced by referring to the descriptions in WO 2015 / 115091 and the like.

[0224] In the present invention, the term "anti-HER3 antibody-drug conjugate" refers to an antibody-drug conjugate according to the present invention in which the antibody is an anti-HER3 antibody.

[0225] The anti-HER3 antibody is preferably an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 26 to 35 of SEQ ID NO: 3, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 50 to 65 of SEQ ID NO: 3, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 98 to 106 of SEQ ID NO: 3, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 24 to 39 of SEQ ID NO: 4, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 56 to 62 of SEQ ID NO: 4, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 95 to 103 of SEQ ID NO: 4, More preferably, the antibody comprises a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 117 of SEQ ID NO: 3, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 113 of SEQ ID NO: 4, Even more preferably, the antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO: 4, or an antibody in which the lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.

[0226] The average number of drug linker bonds per antibody in the anti-HER3 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.

[0227] Anti-HER3 antibody-drug conjugates can be produced by referring to the descriptions in WO 2015 / 155998 and the like.

[0228] In the present invention, the term "anti-TROP2 antibody-drug conjugate" refers to an antibody-drug conjugate according to the present invention in which the antibody is an anti-TROP2 antibody.

[0229] The anti-TROP2 antibody is preferably an antibody comprising a heavy chain comprising a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 50 to 54 of SEQ ID NO:5, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 69 to 85 of SEQ ID NO:5, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 118 to 129 of SEQ ID NO:5, and a light chain comprising a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 44 to 54 of SEQ ID NO:6, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 70 to 76 of SEQ ID NO:6, and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 109 to 117 of SEQ ID NO:6, More preferably, the antibody comprises a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 20 to 140 of SEQ ID NO:5, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 21 to 129 of SEQ ID NO:6, Even more preferably, the antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO:5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO:6, or an antibody in which the lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.

[0230] The average number of drug linker bonds per antibody in the anti-TROP2 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, and even more preferably about 4.

[0231] Anti-TROP2 antibody-drug conjugates can be produced with reference to the descriptions in WO 2015 / 098099, WO 2017 / 002776, and the like.

[0232] In the present invention, the term "anti-B7-H3 antibody-drug conjugate" refers to an antibody-drug conjugate according to the present invention in which the antibody is an anti-B7-H3 antibody.

[0233] The anti-B7-H3 antibody is preferably an antibody comprising a heavy chain comprising a CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 50 to 54 of SEQ ID NO: 7, a CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 69 to 85 of SEQ ID NO: 7, and a CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 118 to 130 of SEQ ID NO: 7, and a light chain comprising a CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 44 to 53 of SEQ ID NO: 8, a CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 69 to 75 of SEQ ID NO: 8, and a CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 108 to 116 of SEQ ID NO: 8, More preferably, it is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 20 to 141 of SEQ ID NO: 7, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 21 to 128 of SEQ ID NO: 8, Even more preferably, the antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 8, or an antibody in which the lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.

[0234] The average number of drug linker bonds per antibody in the anti-B7-H3 antibody-drug conjugate is preferably 2 to 8, more preferably 3 to 5, even more preferably 3.5 to 4.5, and even more preferably about 4.

[0235] The anti-B7-H3 antibody-drug conjugate used in the present invention can be produced with reference to the descriptions in WO 2014 / 057687, WO 2017 / 002776, and the like.

[0236] In the present invention, the term "anti-CDH6 antibody-drug conjugate" refers to an antibody-drug conjugate in which the antibody is an anti-CDH6 antibody.

[0237] The anti-CDH6 antibody is preferably an antibody comprising a heavy chain comprising CDRH1 consisting of the amino acid sequence set forth in amino acid numbers 45 to 54 of SEQ ID NO: 9, CDRH2 consisting of the amino acid sequence set forth in amino acid numbers 69 to 78 of SEQ ID NO: 9, and CDRH3 consisting of the amino acid sequence set forth in amino acid numbers 118 to 130 of SEQ ID NO: 9, and a light chain comprising CDRL1 consisting of the amino acid sequence set forth in amino acid numbers 44 to 54 of SEQ ID NO: 10, CDRL2 consisting of the amino acid sequence set forth in amino acid numbers 70 to 76 of SEQ ID NO: 10, and CDRL3 consisting of the amino acid sequence set forth in amino acid numbers 109 to 116 of SEQ ID NO: 10, More preferably, it is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 20 to 141 of SEQ ID NO: 9, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 21 to 128 of SEQ ID NO: 10, Even more preferably, the antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO: 10, or an antibody in which the lysine residue at the carboxyl terminus of the heavy chain of the antibody is deleted.

[0238] The average number of drug linker bonds per antibody in the anti-CDH6 antibody-drug conjugate used in the present invention is preferably 2 to 8, more preferably 3 to 8, even more preferably 7 to 8, even more preferably 7.5 to 8, and even more preferably about 8.

[0239] The anti-CDH6 antibody-drug conjugate used in the present invention can be produced with reference to the descriptions in International Publication No. 2018 / 212136, etc.

[0240] 4. Kinase inhibitors In the present invention, the term "kinase inhibitor" refers to a drug that inhibits kinases involved in the proliferation of cancer cells and tumor angiogenesis. The kinase inhibitor in the present invention can include at least one selected from the group consisting of CDK4 / 6 inhibitors, mTOR inhibitors, PI3K inhibitors, AKT inhibitors, ERK inhibitors, MEK inhibitors, RAF inhibitors, CDK1 inhibitors, CDK2 inhibitors, CHK1 inhibitors, WEE1 inhibitors, PLK1 inhibitors, Aurora kinase inhibitors, Bcr-Abl inhibitors, Src inhibitors, EPH inhibitors, VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, BTK inhibitors, FLT3 inhibitors, ALK inhibitors, JAK inhibitors, MET inhibitors, CSF-1R inhibitors, NTRK inhibitors, EGFR inhibitors, and HER2 inhibitors.

[0241] The "pharmacologically acceptable salt" of the kinase inhibitor used in the present invention may be either an acid addition salt or a base addition salt. Examples of the acid addition salt include lower alkane sulfonate such as camsylate (camphorsulfonate), mesylate (methanesulfonate), trifluoromethanesulfonate, and ethanesulfonate; arylsulfonate such as tosylate (p-toluenesulfonate) and benzenesulfonate; inorganic acid salts such as phosphate, nitrate, perchlorate, and sulfate; hydrohalide salts such as hydrochloride, hydrobromide, hydroiodide, and hydrofluoride; organic acid salts such as acetate, malate, fumarate, succinate, citrate, tartrate, oxalate, and maleate; and amino acid salts such as ornithine, glutamate, and aspartate. Examples of base addition salts include alkali metal salts such as sodium salt, potassium salt, and lithium salt; alkaline earth metal salts such as calcium salt and magnesium salt; inorganic salts such as ammonium salt; organic amine salts such as dibenzylamine salt, morpholine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, diethylamine salt, triethylamine salt, cyclohexylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, diethanolamine salt, N-benzyl-N-(2-phenylethoxy)amine salt, piperazine salt, tetramethylammonium salt, and tris(hydroxymethyl)aminomethane salt; and amino acid salts such as arginine salt.

[0242] In addition, the kinase inhibitors and pharmacologically acceptable salts thereof used in the present invention may exist as solvates, and these solvates are also included in the kinase inhibitors and pharmacologically acceptable salts thereof used in the present invention.

[0243] In the present invention, the term "CDK4 / 6 inhibitor" refers to a drug that inhibits cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 6 (CDK6). The CDK4 / 6 inhibitor in the present invention may have an effect of inhibiting kinases other than CDK4 / 6. The CDK4 / 6 inhibitor in the present invention is not particularly limited as long as it is a drug having the above-mentioned properties, but is preferably abemaciclib (U.S. Pat. No. 7,855,211), palbociclib (U.S. Pat. No. 6,936,612), ribociclib (U.S. Pat. No. 9,193,732), trilaciclib (WO 2012 / 061156), G1T38 (Oncotarget 2017, 8(26): 42343-42358), PF-06873600 (WO 2018 / 033815), TP-1287 (WO 2016 / 187316), FN-1501 (J Med Chem 2018, 61(4): 1499-1518), and KRX-0601 (WO 1989 / 007105), and pharmacologically acceptable salts thereof.

[0244] In addition, PF-06873600, FN-1501, and pharmacologically acceptable salts thereof are also known as CDK2 inhibitors. In addition, TP-1287 and pharmacologically acceptable salts thereof are also known as CDK1 inhibitors and CDK2 inhibitors. In addition, KRX-0601 and pharmacologically acceptable salts thereof are also known as PI3K inhibitors, CDK1 inhibitors, CDK2 inhibitors, and CHK1 inhibitors.

[0245] In the present invention, the term "mTOR inhibitor" refers to a drug that inhibits mTOR (Mammalian target of rapamycin), a type of serine-threonine kinase. The mTOR inhibitor in the present invention may have an effect of inhibiting kinases other than mTOR. The mTOR inhibitor in the present invention is not particularly limited as long as it is a drug having the above-mentioned properties, but is preferably everolimus (U.S. Pat. No. 5,665,772), sirolimus (U.S. Pat. No. 5,989,591), temsirolimus (U.S. Pat. No. 5,362,718), TAK-228 (Cancer Chemother Pharmacol 2017, 80(2): 261-273), CC-223 (J Med Chem 2015, 58(13): 5323-5333), AZD8055 (Cancer Res 2010, 70(1): 288-98), dactolisib (Invest New Drugs 2015, 33(2): 463-71), Apitolisib (WO 2008 / 070740), Gedatolisib (WO 2009 / 143313), LY3023414 (Mol Cancer Ther 2016, 15(10): 2344-2356), PF-04691502 (Mol Cancer Ther 2011, 10(11): 2189-99), NVP-BGT226 (Ann Oncol 2012, 23(9): 2399-408), and PQR309 (J Med Chem 2017, 60(17): 7524-7538), and pharmacologically acceptable salts thereof.

[0246] In addition, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, and PQR309, and pharmacologically acceptable salts thereof are also known as PI3K inhibitors.

[0247] In the present invention, the term "PI3K inhibitor" refers to a drug that inhibits PI3K (Phosphoinositide 3-kinase), an enzyme that phosphorylates the hydroxyl group at position 3 of the inositol ring of inositol phospholipids. The PI3K inhibitor in the present invention may also have an effect of inhibiting kinases other than PI3K.The PI3K inhibitor in the present invention is not particularly limited as long as it is a drug having the above-mentioned properties, but is preferably taselisib (WO 2014 / 140073), alpelisib (WO 2010 / 029082), TAK-117 (Org Process Res Dev 2017, 21(4): 669-673), GSK2636771 (Clin Cancer Res 2017, 23(19): 5981-92), AZD8186 (J Med Chem 2015, 58(2): 943-962), IPI-549 (ACS Med Chem Lett 2016, 7(9): 862-867), Idelalisib (U.S. Pat. No. 9,469,643), Duvelisib (U.S. Pat. No. 8,193,182), AMG319 (J Med Chem 2015, 58(1): 480-511), Buparlisib (WO 2007 / 084786), Pictilisib (WO 2007 / 129161), Pilaralisib (WO 2007 / 044729), Copanlisib (U.S. Pat. No. 7,511,041), Sonolisib (WO 2003 / 024183), CH5132799 (Bioorg Med Chem Lett 2011, 21(6): 1767-1772), ZSTK474 (J Natl Cancer Inst 2006, 98(8): 545-56), GDC-0077 (WO 2017 / 001645), dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, and rigosertib (WO 2006 / 010152), and pharmacologically acceptable salts thereof.

[0248] Rigosertib and its pharmacologically acceptable salts are also known as CDK1 inhibitors and PLK1 inhibitors.

[0249] The pharmacologically acceptable salt of Copanlisib is preferably a hydrochloride (Copanlisib Hydrochloride).The pharmacologically acceptable salt of Rigosertib is preferably a sodium salt (Rigosertib Sodium).

[0250] In the present invention, the term "AKT inhibitor" refers to a drug that inhibits AKT (also known as Protein Kinase B), a serine-threonine kinase. The AKT inhibitor in the present invention may have an effect of inhibiting kinases other than AKT. The AKT inhibitor in the present invention is not particularly limited as long as it is a drug having the above properties, but preferred examples thereof include Ipatasertib (WO 2008 / 006040), Uprosertib (WO 2008 / 098104), MK-2206 (Mol Cancer Ther 2010, 9(7): 1956-67), BAY1125976 (Int J Cancer 2017, 140(2): 449-454), AZD5363 (Mol Cancer Ther 2012, 11(4): 873-87), and TAS-117 (Cancer Res 2014, 74(16): 4458-69), and pharmacologically acceptable salts thereof.

[0251] The pharmacologically acceptable salt of Ipatasertib is preferably hydrochloride (Ipatasertib Hydrochloride).

[0252] In the present invention, the term "ERK inhibitor" refers to a drug that inhibits extracellular signal-regulated kinase (ERK). The ERK inhibitor in the present invention may have an effect of inhibiting kinases other than ERK. The ERK inhibitor in the present invention is not particularly limited as long as it is a drug having the above properties, but preferred examples thereof include ONC201 (Oncotarget 2014, 5(24): 12728-37), BVD-523 (Mol Cancer Ther 2017, 16(11): 2351-2363), CC-90003 (WO 2014 / 124230), GDC-0994 (J Med Chem 2016, 59(12): 5650-5660), LY3214996 (WO 2016 / 106029), and MK-8353 (ACS Med Chem Lett 2018, 9(7): 761-767), and pharmacologically acceptable salts thereof.

[0253] In the present invention, the term "MEK inhibitor" refers to a drug that inhibits mitogen-activated extracellular signal-regulated kinase (MEK). The MEK inhibitor in the present invention may have an effect of inhibiting kinases other than MEK. The MEK inhibitor in the present invention is not particularly limited as long as it is a drug having the above-mentioned properties, but is preferably trametinib (U.S. Pat. No. 7,378,423), binimetinib (U.S. Pat. No. 7,777,050), selumetinib (WO 2005 / 023251), refametinib (WO 2007 / 014011), pimasertib (WO 2006 / 045514), cobimetinib (U.S. Pat. No. 7,803,839), E6201 (J Pharmacol Exp Ther 2009, 331(2): 485-95), PD-0325901 (Clin Cancer Res 2010, 16(8): 2450-7), RO5126766 (ACS Med Chem Lett 2014, 5(4): 309-14), and GDC-0623 (Bioorg Med Chem Lett 2014, 24(19): 4714-4723), and pharmacologically acceptable salts thereof.

[0254] Trametinib is preferably a dimethyl sulfoxide adduct.

[0255] In the present invention, the term "RAF inhibitor" refers to a drug that inhibits the kinase activity of RAF (preferably BRAF). The RAF inhibitor in the present invention may also have an effect of inhibiting kinases other than RAF. The RAF inhibitor in the present invention is not particularly limited as long as it is a drug having the above-mentioned properties, but is preferably regorafenib (U.S. Pat. No. 7,351,834), sorafenib (U.S. Pat. No. 7,235,576), vemurafenib (U.S. Pat. No. 7,504,509), dabrafenib (U.S. Pat. No. 7,994,185), encorafenib (U.S. Pat. No. 8,501,758), RAF265 (ACS Med Chem Lett 2015, 6(9): 961-5), GDC-5573 (WO 2013 / 100632), LY3009120 (J Med Chem 2015, 58(10): 4165-4179), and RO5126766, and pharmacologically acceptable salts thereof.

[0256] Regorafenib and its pharmacologically acceptable salts are also known as VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, and FGFR inhibitors. Sorafenib and its pharmacologically acceptable salts are also known as VEGFR inhibitors, KIT inhibitors, RET inhibitors, PDGFR inhibitors, FGFR inhibitors, and FLT3 inhibitors.

[0257] Regorafenib is preferably a hydrate. A pharmacologically acceptable salt of sorafenib is prefer...

Claims

1. A pharmaceutical composition comprising an antibody-drug conjugate and a kinase inhibitor administered in combination, comprising: The antibody-drug conjugate has the formula [Formula 1] (In the formula, A represents the binding site with the antibody.) and an antibody-drug conjugate in which the drug linker represented by the formula: The pharmaceutical composition, wherein the kinase inhibitor is at least one selected from the group consisting of a CDK4 / 6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, an AKT inhibitor, an ERK inhibitor, a MEK inhibitor, a RAF inhibitor, a CDK1 inhibitor, a CDK2 inhibitor, a CHK1 inhibitor, a WEE1 inhibitor, a PLK1 inhibitor, an Aurora kinase inhibitor, a Bcr-Abl inhibitor, a Src inhibitor, an EPH inhibitor, a VEGFR inhibitor, a KIT inhibitor, a RET inhibitor, a PDGFR inhibitor, an FGFR inhibitor, a BTK inhibitor, a FLT3 inhibitor, an ALK inhibitor, a JAK inhibitor, a MET inhibitor, a CSF-1R inhibitor, a NTRK inhibitor, an EGFR inhibitor, and a HER2 inhibitor.

2. The pharmaceutical composition according to claim 1, wherein the kinase inhibitor is at least one selected from the group consisting of a CDK4 / 6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, a RAF inhibitor, a VEGFR inhibitor, a KIT inhibitor, a RET inhibitor, a PDGFR inhibitor, an FGFR inhibitor, a FLT3 inhibitor, an ALK inhibitor, a CSF-1R inhibitor, an EGFR inhibitor, and a HER2 inhibitor.

3. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

4. The pharmaceutical composition according to claim 3, wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

5. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is an mTOR inhibitor.

6. The pharmaceutical composition according to claim 5, wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

7. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a PI3K inhibitor.

8. The pharmaceutical composition according to claim 7, wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, pilaralisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

9. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a RAF inhibitor.

10. The pharmaceutical composition according to claim 9, wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

11. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a VEGFR inhibitor.

12. The pharmaceutical composition according to claim 11, wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ilorasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

13. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a KIT inhibitor.

14. The pharmaceutical composition according to claim 13, wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, ilorasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

15. The pharmaceutical composition according to claim 2 , wherein the kinase inhibitor is a RET inhibitor.

16. The pharmaceutical composition according to claim 15, wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

17. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a PDGFR inhibitor.

18. The pharmaceutical composition according to claim 17, wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

19. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is an FGFR inhibitor.

20. The pharmaceutical composition according to claim 19, wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

21. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is an FLT3 inhibitor.

22. The pharmaceutical composition according to claim 21, wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

23. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is an ALK inhibitor.

24. The pharmaceutical composition according to claim 23, wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

25. The pharmaceutical composition of claim 2, wherein the kinase inhibitor is a CSF-1R inhibitor.

26. The pharmaceutical composition according to claim 25, wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

27. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is an EGFR inhibitor.

28. The pharmaceutical composition according to claim 27, wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

29. The pharmaceutical composition of claim 2 , wherein the kinase inhibitor is a HER2 inhibitor.

30. 30. The pharmaceutical composition of claim 29, wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

31. The pharmaceutical composition according to any one of claims 1 to 30, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

32. The pharmaceutical composition of claim 31 , wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

33. The pharmaceutical composition of claim 32, wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising a CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 of SEQ ID NO: 1, a CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 of SEQ ID NO: 1, and a CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 of SEQ ID NO: 1, and a light chain comprising a CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 of SEQ ID NO: 2, a CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 of SEQ ID NO: 2, and a CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 of SEQ ID NO:

2.

34. The pharmaceutical composition of claim 32, wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO:

2.

35. The pharmaceutical composition of claim 32, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

36. The pharmaceutical composition of claim 32, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 of SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 of SEQ ID NO:

2.

37. The pharmaceutical composition according to any one of claims 32 to 36, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

38. The pharmaceutical composition of claim 31 , wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

39. The pharmaceutical composition of claim 38, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

4.

40. The pharmaceutical composition of claim 39, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

41. The pharmaceutical composition according to any one of claims 38 to 40, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

42. The pharmaceutical composition of claim 31 , wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

43. The pharmaceutical composition according to claim 42, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO:5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO:

6.

44. The pharmaceutical composition of claim 43, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

45. The pharmaceutical composition according to any one of claims 42 to 44, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.

5.

46. The pharmaceutical composition of claim 31, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

47. The pharmaceutical composition according to claim 46, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO:

8.

48. The pharmaceutical composition of claim 47, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

49. The pharmaceutical composition according to any one of claims 46 to 48, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.

5.

50. The pharmaceutical composition of claim 31 , wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

51. The pharmaceutical composition according to claim 50, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO:

10.

52. The pharmaceutical composition of claim 51, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

53. The pharmaceutical composition according to any one of claims 50 to 52, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

54. The pharmaceutical composition according to any one of claims 1 to 53, wherein the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in different formulations and are administered simultaneously or at different times.

55. 55. The pharmaceutical composition of any one of claims 1 to 54, for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

56. 56. The pharmaceutical composition of claim 55 for the treatment of breast cancer.

57. 56. The pharmaceutical composition of claim 55 for the treatment of colon cancer.

58. 56. The pharmaceutical composition of claim 55 for the treatment of gastric cancer.

59. 56. The pharmaceutical composition of claim 55 for the treatment of lung cancer.

60. 56. The pharmaceutical composition of claim 55 for the treatment of pancreatic cancer.

61. 56. The pharmaceutical composition of claim 55 for the treatment of renal cancer.

62. 56. The pharmaceutical composition of claim 55 for the treatment of ovarian cancer.

63. A pharmaceutical composition comprising an antibody-drug conjugate and a kinase inhibitor administered in combination, comprising: The antibody-drug conjugate has the formula [chemical 2] (In the formula, the drug linker is bound to the antibody via a thioether bond, and n represents the average number of drug linkers bound per antibody.) an antibody-drug conjugate represented by The pharmaceutical composition, wherein the kinase inhibitor is at least one selected from the group consisting of a CDK4 / 6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, an AKT inhibitor, an ERK inhibitor, a MEK inhibitor, a RAF inhibitor, a CDK1 inhibitor, a CDK2 inhibitor, a CHK1 inhibitor, a WEE1 inhibitor, a PLK1 inhibitor, an Aurora kinase inhibitor, a Bcr-Abl inhibitor, a Src inhibitor, an EPH inhibitor, a VEGFR inhibitor, a KIT inhibitor, a RET inhibitor, a PDGFR inhibitor, an FGFR inhibitor, a BTK inhibitor, a FLT3 inhibitor, an ALK inhibitor, a JAK inhibitor, a MET inhibitor, a CSF-1R inhibitor, a NTRK inhibitor, an EGFR inhibitor, and a HER2 inhibitor.

64. The pharmaceutical composition of claim 63, wherein the kinase inhibitor is at least one selected from the group consisting of a CDK4 / 6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, a RAF inhibitor, a VEGFR inhibitor, a KIT inhibitor, a RET inhibitor, a PDGFR inhibitor, an FGFR inhibitor, a FLT3 inhibitor, an ALK inhibitor, a CSF-1R inhibitor, an EGFR inhibitor, and a HER2 inhibitor.

65. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a CDK4 / 6 inhibitor.

66. The pharmaceutical composition of claim 65, wherein the CDK4 / 6 inhibitor is abemaciclib, palbociclib, ribociclib, trilaciclib, G1T38, PF-06873600, TP-1287, FN-1501, or KRX-0601, or a pharmacologically acceptable salt thereof.

67. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is an mTOR inhibitor.

68. The pharmaceutical composition of claim 67, wherein the mTOR inhibitor is everolimus, sirolimus, temsirolimus, TAK-228, CC-223, AZD8055, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, or PQR309, or a pharmacologically acceptable salt thereof.

69. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a PI3K inhibitor.

70. The pharmaceutical composition according to claim 69, wherein the PI3K inhibitor is taselisib, alpelisib, TAK-117, GSK2636771, AZD8186, IPI-549, idelalisib, duvelisib, AMG319, buparlisib, pictilisib, piralalisib, copanlisib, sonolisib, CH5132799, ZSTK474, GDC-0077, dactolisib, apitolisib, jedatolicib, LY3023414, PF-04691502, NVP-BGT226, PQR309, KRX-0601, or rigosertib, or a pharmacologically acceptable salt thereof.

71. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a RAF inhibitor.

72. The pharmaceutical composition of claim 71, wherein the RAF inhibitor is regorafenib, sorafenib, vemurafenib, dabrafenib, encorafenib, RAF265, GDC-5573, LY3009120, or RO5126766, or a pharmacologically acceptable salt thereof.

73. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a VEGFR inhibitor.

74. The pharmaceutical composition according to claim 73, wherein the VEGFR inhibitor is regorafenib, sorafenib, vandetanib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, cabozantinib, tivozanib, brivanib, linifanib, lucitanib, ilorasertib, or ENMD-2076, or a pharmacologically acceptable salt thereof.

75. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a KIT inhibitor.

76. The pharmaceutical composition of claim 75, wherein the KIT inhibitor is regorafenib, sorafenib, imatinib, ilorasertib, sunitinib, pazopanib, lenvatinib, or dasatinib, or a pharmacologically acceptable salt thereof.

77. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a RET inhibitor.

78. The pharmaceutical composition according to claim 77, wherein the RET inhibitor is regorafenib, sorafenib, vandetanib, lenvatinib, or sunitinib, or a pharmacologically acceptable salt thereof.

79. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a PDGFR inhibitor.

80. The pharmaceutical composition of claim 79, wherein the PDGFR inhibitor is regorafenib, sorafenib, sunitinib, axitinib, pazopanib, lenvatinib, nintedanib, irolasertib, imatinib, nilotinib, or dasatinib, or a pharmacologically acceptable salt thereof.

81. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is an FGFR inhibitor.

82. The pharmaceutical composition of claim 81, wherein the FGFR inhibitor is regorafenib, sorafenib, lenvatinib, nintedanib, axitinib, or pazopanib, or a pharmacologically acceptable salt thereof.

83. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a FLT3 inhibitor.

84. The pharmaceutical composition according to claim 83, wherein the FLT3 inhibitor is gilteritinib, quizartinib, midostaurin, sorafenib, ilorasertib, ENMD-2076, or sunitinib, or a pharmacologically acceptable salt thereof.

85. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is an ALK inhibitor.

86. 86. The pharmaceutical composition of claim 85, wherein the ALK inhibitor is brigatinib, crizotinib, ceritinib, alectinib, or lorlatinib, or a pharmacologically acceptable salt thereof.

87. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a CSF-1R inhibitor.

88. The pharmaceutical composition of claim 87, wherein the CSF-1R inhibitor is pexidartinib, BLZ-945, JNJ-40346527, JNJ-28312141, irolasertib, imatinib, sunitinib, or axitinib, or a pharmacologically acceptable salt thereof.

89. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is an EGFR inhibitor.

90. 90. The pharmaceutical composition of claim 89, wherein the EGFR inhibitor is gefitinib, erlotinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

91. 65. The pharmaceutical composition of claim 64, wherein the kinase inhibitor is a HER2 inhibitor.

92. 92. The pharmaceutical composition of claim 91, wherein the HER2 inhibitor is tucatinib, neratinib, mubritinib, lapatinib, pyrotinib, or poziotinib, or a pharmacologically acceptable salt thereof.

93. The pharmaceutical composition of any one of claims 63 to 92, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody, an anti-HER3 antibody, an anti-TROP2 antibody, an anti-B7-H3 antibody, or an anti-CDH6 antibody.

94. The pharmaceutical composition of claim 93, wherein the antibody in the antibody-drug conjugate is an anti-HER2 antibody.

95. The pharmaceutical composition of claim 94, wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising a CDRH1 having the amino acid sequence set forth in amino acid numbers 26 to 33 of SEQ ID NO: 1, a CDRH2 having the amino acid sequence set forth in amino acid numbers 51 to 58 of SEQ ID NO: 1, and a CDRH3 having the amino acid sequence set forth in amino acid numbers 97 to 109 of SEQ ID NO: 1, and a light chain comprising a CDRL1 having the amino acid sequence set forth in amino acid numbers 27 to 32 of SEQ ID NO: 2, a CDRL2 having the amino acid sequence set forth in amino acid numbers 50 to 52 of SEQ ID NO: 2, and a CDRL3 having the amino acid sequence set forth in amino acid numbers 89 to 97 of SEQ ID NO:

2.

96. The pharmaceutical composition of claim 94, wherein the anti-HER2 antibody is an antibody comprising a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 120 of SEQ ID NO: 1, and a light chain comprising a light chain variable region consisting of the amino acid sequence set forth in amino acid numbers 1 to 107 of SEQ ID NO:

2.

97. The pharmaceutical composition of claim 94, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

2.

98. The pharmaceutical composition of claim 94, wherein the anti-HER2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 449 of SEQ ID NO: 1 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 1 to 214 of SEQ ID NO:

2.

99. The pharmaceutical composition according to any one of claims 94 to 98, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

100. The pharmaceutical composition of claim 93, wherein the antibody in the antibody-drug conjugate is an anti-HER3 antibody.

101. The pharmaceutical composition of claim 100, wherein the anti-HER3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in SEQ ID NO: 3 and a light chain consisting of the amino acid sequence set forth in SEQ ID NO:

4.

102. The pharmaceutical composition of claim 101, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-HER3 antibody is deleted.

103. The pharmaceutical composition according to any one of claims 100 to 102, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

104. The pharmaceutical composition of claim 93, wherein the antibody in the antibody-drug conjugate is an anti-TROP2 antibody.

105. The pharmaceutical composition of claim 104, wherein the anti-TROP2 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 470 of SEQ ID NO: 5 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 234 of SEQ ID NO:

6.

106. The pharmaceutical composition of claim 105, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-TROP2 antibody is deleted.

107. The pharmaceutical composition according to any one of claims 104 to 106, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.

5.

108. The pharmaceutical composition of claim 93, wherein the antibody in the antibody-drug conjugate is an anti-B7-H3 antibody.

109. The pharmaceutical composition according to claim 108, wherein the anti-B7-H3 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO:

8.

110. The pharmaceutical composition of claim 109, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-B7-H3 antibody is deleted.

111. The pharmaceutical composition according to any one of claims 108 to 110, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 3.5 to 4.

5.

112. The pharmaceutical composition of claim 93, wherein the antibody in the antibody-drug conjugate is an anti-CDH6 antibody.

113. The pharmaceutical composition of claim 112, wherein the anti-CDH6 antibody is an antibody comprising a heavy chain consisting of the amino acid sequence set forth in amino acid numbers 20 to 471 of SEQ ID NO: 9 and a light chain consisting of the amino acid sequence set forth in amino acid numbers 21 to 233 of SEQ ID NO:

10.

114. The pharmaceutical composition of claim 113, wherein the lysine residue at the carboxyl terminus of the heavy chain of the anti-CDH6 antibody is deleted.

115. The pharmaceutical composition according to any one of claims 112 to 114, wherein the average number of drug linkers bound per antibody in the antibody-drug conjugate is in the range of 7 to 8.

116. The pharmaceutical composition according to any one of claims 63 to 115, wherein the antibody-drug conjugate and the kinase inhibitor are contained as active ingredients in different formulations and are administered simultaneously or at different times.

117. The pharmaceutical composition of any one of claims 63 to 116 for the treatment of at least one selected from the group consisting of breast cancer, gastric cancer, colorectal cancer, lung cancer, esophageal cancer, head and neck cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, Paget's disease, pancreatic cancer, ovarian cancer, uterine carcinosarcoma, urothelial cancer, prostate cancer, bladder cancer, gastrointestinal stromal tumor, gastrointestinal stromal tumor, cervical cancer, squamous cell carcinoma, peritoneal cancer, liver cancer, hepatocellular carcinoma, uterine cancer, kidney cancer, vulvar cancer, thyroid cancer, penile cancer, leukemia, malignant lymphoma, plasmacytoma, myeloma, glioblastoma multiforme, osteosarcoma, sarcoma, and melanoma.

118. 118. The pharmaceutical composition of claim 117 for the treatment of breast cancer.

119. The pharmaceutical composition of claim 117 for the treatment of colon cancer.

120. 118. The pharmaceutical composition of claim 117 for the treatment of gastric cancer.

121. 118. The pharmaceutical composition of claim 117 for the treatment of lung cancer.

122. The pharmaceutical composition of claim 117 for the treatment of pancreatic cancer.

123. 118. The pharmaceutical composition of claim 117 for the treatment of renal cancer.

124. 118. The pharmaceutical composition of claim 117 for the treatment of ovarian cancer.

Citation Information

Patent Citations

  • anti-her3 antibody-drug conjugate

    JP2017503784A

  • Antibody-drug conjugate

    WO2014057687A1

  • Antibody-drug conjugate produced by binding through linker having hydrophilic structure

    WO2014061277A1

  • Anti-trop2 antibody-drug conjugate

    WO2015098099A1

  • Anti-her2 antibody-drug conjugate

    WO2015115091A1